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Retrosintezno zasnovana in silico optimizacija protivirusnih učinkovin z delovanjem na 
3C in 3CL proteaze 
Povzetek: 
Pandemija koronavirusne bolezni 2019 (COVID-19) je razkrila nepripravljenost človeštva na 
boj z izbruhi novih virusov. Kljub temu, da smo v zadnjih dveh desetletjih doživeli že dve 
epidemiji s koronavirusi povezanih bolezni (SARS in MERS), nam je ob izbruhu COVID-19 
brez rešitev za zdravljenje okužb s koronavirusi ostalo le upanje na reindikacijo že odobrenih 
zdravil ali uspešen razvoj cepiv. Razvoj cepiv se ne more začeti pred pojavom bolezni in 
reindikacija zdravil je prej stvar sreče kot primerna strategija javnega zdravja. Raziskave 
protivirusnih učinkovin zato ostajajo ključnega pomena in ponujajo osnovo za spopadanje z 
izbruhi virusnih bolezni v prihodnosti, katerih tveganje se ne sme ponovno zanemariti. 
Številna zdravila za zdravljenje okužb z virusom HIV in hepatitisom C delujejo na osnovi 
zaviranja virusnih proteaz. Razvoj zaviralcev virusnih proteaz predstavlja preboj v 
obvladovanju in zdravljenju okužb s tema virusoma. Ker sta proteazi HIV in virusa hepatitisa C 
po strukturi drugačni od proteaz drugih virusov, te spojine ne omogočajo širokospektralnega 
protivirusnega delovanja (učinkovitosti med različnimi pripadniki dveh ali več virusnih družin). 
Pikornavirusi (Picornaviridae), kalicivirusi (Caliciviridae) in koronavirusi (Coronaviridae) so 
zelo razširjeni, povzročajo pogoste izbruhe in resno socialno-ekonomsko škodo po vsem svetu. 
Trenutna strategija obvladovanja izbruhov je le spodbujanje higiene, preventiva s cepljenjem in 
simptomatsko zdravljenje okužb. Virusni proteazi 3C proteaza (3Cpro) ter funkcionalno in 
strukturno podobna 3C podobna proteaza (3CLpro) igrata ključno vlogo pri virusni replikaciji ter 
imata izrazito podobno aktivno mesto med pripadniki teh treh virusnih družin. Iz teh razlogov 
sta odlični tarči za razvoj širokospektralnih protivirusnih učinkovin. Kljub temu trenutno ni 
nobenih komercialno dostopnih zdravil, ki delujejo na osnovi inhibicije 3Cpro ali 3CLpro. 
Širokospektralni zaviralci 3C/3CLpro lahko predstavljajo rešitev za številne že iz preteklosti 
dobro poznane človeške bolezni, med katerimi so na primer virusni gastroenteritis, prehlad, 
poliomielitis, herpangina, pleurodinija, virusni meningitis in virusni hepatitis A. Poleg tega so 
zaviralci 3C/3CLpro predstavljali izhodišče načrtovanja in optimizacije zdravilnih učinkovin v 
namen zdravljenja COVID-19. 
Leta 2019 so na Inštitutu za farmacijo Freie Universität Berlin odkrili spojino MLC3 - nov tip 
ireverzibilnega zaviralca 3Cpro Enterovirusa 68 (EV68), ki se specifično veže na cistein v 
aktivnem mestu in z njim tvori Meisenheimerjev kompleks. Meisenheimerjev kompleks je 
anionski intermediat aromatske nukleofilne substitucije (SNAr), ki nastane ob kovalentni adiciji 
nukleofila na heteroaromatske ali aromatske obroče, aktivirane z elektron-privlačno skupino. 
Spojina MLC3 je prvi zaviralec cisteinske proteaze s tem mehanizmom delovanja. 
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V tej nalogi opisujemo dva pristopa k optimizaciji spojine vodnice MLC3 z namenom povišanja 
afinitete za vezavo na EV68-3Cpro ter s tem višjim potencialom za učinkovitost in s 
selektivnostjo delovanja povezanim nižjim potencialom za stranske učinke ali toksičnost 
MLC3. Ta spojina ima zaradi svoje nizke molske mase (267.31 Da) lastnosti fragmenta in 
zaseda le S1 žepek aktivnega mesta EV68-3Cpro. EV68 sam po sebi sicer nima pomembne vloge 
kot človeški patogen, vendar primerjava kristalnih struktur 3Cpro kaže na reprezentativni značaj 
EV68-3Cpro glede na strukturo 3Cpro različnih pikornavirusov. S tem imajo spojine, optimizirane 
za zaviranje EV68-3Cpro, večje možnosti za zdravljenje okužb s pikornavirusi nasploh. 
Prepoznali smo dva ključna strukturna elementa MLC3. Prvi strukturni element je 1,2,4-triazol, 
ki s tvorbo medmolekulskih interakcij v S1 žepku aktivnega mesta 3Cpro pogojuje selektivnost 
delovanja in s tem potencialno nižjo toksičnost derivatov. Drugi strukturni element je 5-metil-
pirimidin-2-il sulfon - kovalentna bojna glava, ki reagira s cisteinom aktivnega mesta 3Cpro in s 
tem pogojuje učinkovitost inhibicije. Na osnovi pregleda literature in molekulskega sidranja 
MLC3 v aktivno mesto EV68-3Cpro predstavljamo dve hipotezi o vezavi MLC3 in s tem 
povezana farmakoforja, tvorjena z namenom virtualnega rešetanja derivatov MLC3. 
Prva metoda optimizacije je bila »rast fragmenta« - razvoj derivatov z dodajanjem substituentov, 
ki tvorijo dodatne interakcije z aktivnim mestom, hkrati pa ohranjajo že obstoječe interakcije 
ogrodja, ki ga predstavlja spojina MLC3. Z namenom racionalne izbire derivatov s stališča 
zmožnosti dobave in proizvodnje, smo v prvem pristopu optimizacije združili rast fragmenta in 
retrosintezno analizo. 
Retrosintezna analiza oz. retrosinteza je strategija, ki se uporablja pri načrtovanju organske 
sinteze. Začne se s ciljno molekulo in jo poenostavi do reaktanta nižje ali podobne strukturne 
zapletenosti. Ta korak se ponavlja, dokler ne pridemo do komercialno dostopnih reaktantov iz 
katerih lahko sintetiziramo želen produkt. V namen racionalnega iskanja možnih derivatov smo 
uporabili retrosintezo, da smo prišli do odgovorov na naslednja vprašanja: 
• Na katere prekurzorje je možno poenostaviti strukturo derivatov MLC3? 
• Katere standardne (ali v literaturi opisane) sintezne korake lahko uporabimo za 
pridobitev derivatov, ki vsebujejo 1,2,4-triazol in 5-metil-pirimidin-2-il sulfon na 
primerni medsebojni razdalji za inhibicijo 3Cpro? 
• Po izbiri določene sintezne poti - kolikšno je najmanjše število sinteznih korakov, ki jih 
potrebujemo za pridobitev strukturno raznolikih derivatov? 
Z odkritjem komercialno dostopnih reaktantov za sintezo derivatov in uporabo analitične 
platforme KNIME smo ustvarili oziroma »in silico sintetizirali« virtualno knjižnico derivatov 
spojine MLC3. V virtualni knjižnici so bili posebej navedeni bodisi vsi možni stereoizomeri 
produktov bodisi večinski stereoizomer sinteze glede na literaturo. Po filtraciji produktov z 
reaktivnimi kemijskimi zvrstmi in večkratnih vnosov iste spojine, ki so nastali zaradi 




Spojine, ki so glede na virtualno rešetanje s programom LigandScout ustrezale vsaj enemu 
izmed dveh farmakoforjev, so bile sidrane v aktivno mesto EV68-3Cpro. Za vsako spojino je bilo 
s programom GOLD proizvedeno do 10 konformacij v aktivnem mestu, ki smo jih nato s 
programom SZYBKI geometrijsko optimizirali. Optimizirane konformacije smo nato z 
virtualnim rešetanjem rigidnih konformacij ponovno ocenili glede na prileganje značilnostim 
izvirne farmakoforne poizvedbe. Izrazito ugodne interakcije z encimom smo z vizualnim 
pregledom prepoznali pri devetnajstih derivatih, ki so predstavljeni v nalogi. 
Drugi pristop k optimizaciji je optimizacija ogrodja samega. Glede na rezultate analize razmerja 
med strukturo in aktivnostjo MLC3 lahko kasneje optimiziramo tudi ogrodje, ki je trenutno 
predstavljalo osnovo vseh derivatov. V katalogih komercialno dostopnih spojin smo odkrili 
trinajst strukturnih analogov MLC3, ki so navedeni za nadaljnje in vitro preskuse. V nekaterih 
primerih je optimizacija ogrodja lahko direktno implementirana z zamenjavo primarnega 
reaktanta, v kolikor je ta dobavljiv. 
Sprva smo načrtovali razvoj zaviralcev izključno pikornavirusne 3Cpro. Ker je struktura S1 
žepka ena glavnih skupnih značilnosti 3Cpro in 3CLpro, smo se ob izbruhu COVID-19 odločili in 
silico ovrednotiti še potencial protivirusne učinkovitosti derivatov MLC3 na koronaviruse. To 
smo naredili v zadnjem koraku z molekulskim sidranjem izbranih derivatov v aktivno mesto 
3CLpro SARS-CoV-2. Derivati MLC3 izkazujejo nizki potencial za inhibicijo SARS-CoV-2-
3CLpro zaradi prevelike bojne glave. Na osnovi literature so za nadaljnje raziskave predlagane 
alternativne bojne glave, ki bi s cisteinom lahko reagirale po istem mehanizmu. 





Retrosynthesis-Driven In Silico Optimization of Antiviral Agents Targeting 3C and 
3C-Like Proteases 
Abstract: 
There is an urgent unmet need for the development of therapies to treat a wide range of 
devastating viral diseases for which there are no accessible curative medications. Antiviral 
research remains essential and provides critical resources for tackling viral disease outbreaks in 
the future, the risk of which should not be underestimated again. The 3C protease (3Cpro) and 
the functionally and structurally similar 3C-like protease (3CLpro) play an essential role in viral 
replication and have a remarkably conserved active site among different virus species, making 
them an excellent target for the treatment of picornavirus-, calicivirus-, and/or 
coronavirus-induced diseases. 
In this thesis, we describe a retrosynthesis-based approach to the optimization of MLC3 – a 
novel Meisenheimer complex-forming inhibitor of Enterovirus 68 3Cpro which is presumed to 
occupy only the S1 pocket of the active site. Since the S1 pocket structure is one of the main 
characteristics linking the 3CLpro to the 3Cpro, the broad-spectrum inhibitor potential of the 
selected derivatives was examined in silico following the enterovirus-focused optimization. 
The optimization is planned by a combination of two approaches. The first one is fragment 
growing – the addition of substituents that form additional interactions with the active site, while 
retaining the preexisting ones of the MLC3 scaffold. Retrosynthesis and an analytics platform 
were used to identify available starting materials allowing the synthesis of 153,675 derivatives. 
Two binding hypotheses of MLC3 are presented, and two pharmacophores optimized for the 
screening of the derivatives were created based on them. The hits of the pharmacophore-based 
virtual screenings were docked and energy minimized. Each compound was scored by how well 
it fulfilled the features of the original query pharmacophore. Favorable enzyme-substituent 
interactions were recognized by visual inspection in nineteen derivatives. 
The second approach is the structure-activity relationship analysis of the MLC3 scaffold. 
Thirteen MLC3 structural analogs have been found in the catalogs of commercially available 
compounds and are listed for subsequent in vitro assays. 





1.1 FACING THE CURRENT AND EMERGING VIRAL DISEASES 
The coronavirus disease 2019 (COVID-19) pandemic has exposed humanity’s unpreparedness 
to combat outbreaks of novel viruses. Being equipped with no approved coronavirus (CoV) 
drugs despite two warning hits of CoV-related outbreaks within the past two decades (1) has 
left us barely hopeful of prompt success in drug repurposing or vaccine development. Greater 
investment in the research of drugs targeting broadly conserved viral targets would have been 
of essential importance. Especially interesting are the structurally conserved enzyme active sites 
which are necessary for the replication efficiency and the pathogenicity of a virus. 
One of these targets are the functionally analogous 3C and 3C-like protease (3Cpro and 3CLpro 
respectively), encoded in the genome of picornaviruses, caliciviruses, and coronaviruses. These 
three viral families of medically and economically influential viruses can be grouped in the 
picornavirus-like supercluster (2). Among them is also the pathogen causing COVID-19 - the 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The picornavirus 3Cpro and 
coronavirus 3CLpro have a pivotal role in viral replication and are promising antiviral targets, 
with 3CLpro even being nicknamed as “the Achilles’ heel of coronaviruses” (3). 
In addition to the direct and weighty effect of the disease on the world’s health and wellbeing, 
the COVID-19 pandemic also represents an obstacle for immunization efforts and puts millions 
of children throughout the world at risk of diseases like polio (a picornavirus-induced disease) 
(4). An antiviral agent exploiting the similarities of the 3Cpro and 3CLpro would bring a solution 
to a multitude of such diseases without accessible curative treatments. 
Enterovirus 68 (EV68) does not have a major role as a human pathogen. However, a comparison 
of the 3Cpro crystal structures indicates an intermediate position of the EV68-3Cpro between the 
structural characteristics of human rhinovirus 2 3Cpro and the corresponding enzymes of other 
enteroviruses. Therefore, compounds optimized for inhibition of the EV68 enzyme might have 
a higher chance of broad-spectrum antiviral activity targeting picornaviruses in general (5). 
The final in vitro tests are planned to be performed on Enterovirus 68 3Cpro (EV68-3Cpro) and 
SARS-CoV-2-3CLpro, representatives of the Picornaviridae and Coronaviridae families 
respectively. The following two subchapters summarize the picornavirus- and coronavirus-
induced diseases that could be treated by the development of 3Cpro/3CLpro inhibitors. Next to 
these two families, the picornavirus-like supercluster also includes the Caliciviridae family of 
viruses. A well-known example of caliciviruses are noroviruses (NVs) - the most common cause 
of food and waterborne acute viral gastroenteritis (2). 
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1.1.1 PICORNAVIRUS-INDUCED DISEASES 
Picornaviruses are small nonenveloped viruses with a single-stranded positive-sense RNA 
genome (Baltimore class IV). The name is a composite of pico-RNA-virus, meaning 'very small 
RNA virus', and describes all viruses belonging to the Picornaviridae family– one of the largest 
families with medically and economically important viral pathogens. Picornaviruses cause 
outbreaks and diseases in a wide range of plants, insects, and vertebrates. Six genera are 
associated with human infections: Enterovirus, Hepatovirus, Cardiovirus, Parechovirus, 
Kobuvirus, and Cosavirus (6).  
Genus Enterovirus contains most of the important human pathogens of the family. Enteroviruses 
(EVs) preferably replicate in the gastrointestinal tract, hence the name (enteron Gr. for 
intestines), and are the third most frequent pathogen in acute gastroenteritis in developed 
nations (7). Infections are frequent and mostly asymptomatic but can cause a multitude of 
symptoms affecting various organs. Examples of subgenera include rhino-, polio-, 
coxsackieviruses, and numbered EV species, e.g. Enterovirus 71 (EV71) (8).  
Human rhinoviruses (HRVs), named from rhinos Gr. for “of the nose”, are the most common 
cause of upper respiratory tract infection (URTI) and are the pathogen behind most common 
colds, and exacerbations of chronic obstructive pulmonary disease (COPD) and asthma (9, 
10). COPD and URTIs are ranked as the third and the fourth leading cause of death respectively 
by the World Health Organization (11). Attaining a single effective vaccination against HRVs 
is unlikely due to lack of cross-neutralization in more than 100 serotypes, and antiviral 
medication may be the only treatment/prophylactic option. Currently, no approved drugs of this 
type are available (9). 
Poliovirus (PV) is the cause of the highly infectious poliomyelitis (polio). Its symptoms are 
fever, fatigue, headache, emesis, stiff neck and limb pain. About 1 in 200 infections lead to 
irreversible paralysis and 5-10% of paralyzed cases result in death due to the paralysis of the 
respiratory muscles. Although the development of a preventive vaccine led to over 99% 
reduction of cases in the past 30 years, the failure to eradicate it could lead to 200,000 new cases 
yearly worldwide within a decade. There is currently no known treatment once infected (12).  
Coxsackieviruses are divided into two groups. Coxsackie A viruses (CVAs) usually cause mild 
pediatric infections, but can sometimes also cause notable diseases in adults, like acute 
hemorrhagic conjunctivitis (the “pink eye”) or herpangina (painful mouth blisters). 
Coxsackie B viruses (CVBs) can cause myocarditis (heart inflammation), pancreatitis 
(pancreas inflammation), pleurodynia (flu-like infection with severe pain of the lower chest), 
and glomerulonephritis (inflammation of the glomeruli in the kidneys) (13). 
Coxsackievirus A16 (CVA16) and EV71 are the main causes of hand, foot-and-mouth disease 
(HFMD), a common illness mainly affecting children. Several outbreaks of HFMD have 
occurred throughout the world since the 1970s. Common symptoms include fever, rashes on 
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hands, feet, and buttocks, and ulcers in the oral cavity. HFMD usually resolves on its own, 
however, in a small proportion of cases it leads to encephalitis, paralysis, or even 
cardiopulmonary failure and death. No treatment is available for HFMD, but several vaccines 
are in development, most of which target a single virus species (14). 
Despite the similar name, foot-and-mouth disease virus (FMDV) is not an Enterovirus but 
belongs to the Aphthovirus genus of the picornaviruses and causes foot-and-mouth disease - 
one of the most contagious and economically influential viral animal diseases infecting cattle, 
sheep, goats, and swine. FMDV does not infect humans (15). 
Almost any EV can induce central nervous system symptoms of various severities. EVs are the 
most common cause of viral meningitis, which can only be treated symptomatically. Most cases 
carry good prognosis, but the accompanied fever can be medication-resistant, and prolonged 
severe headaches often need opiate management. Seizures, unusual behavior, personality 
changes, and cognitive impairment may be caused by progression of meningitis to 
meningoencephalitis (8). EVs are also associated with chronic fatigue syndrome (16). 
Hepatitis A virus (HAV), the only species of the Hepatovirus genus, is the most common cause 
of viral hepatitis with almost 1.4 million infections each year globally, 11%–22% of those 
requiring hospitalization (17). 
1.1.2 CORONAVIRUS-INDUCED DISEASES 
CoVs are enveloped viruses named so for the typical crown-like shape of the viral particles. 
Their genetic material is encoded in a positive-sense single-stranded RNA genome (Baltimore 
class IV) which is also the largest of all RNA viruses. CoVs infect a wide range of vertebrates 
and are a major cause of viral respiratory infections worldwide (18). 
Seven human CoVs are currently known. Common symptoms of the previously mentioned 
COVID-19 are fever (83%), cough (82%), and dyspnea (31%). SARS-CoV-2 is already the 
third CoV responsible for a major outbreak in the past two decades. The first was severe acute 
respiratory syndrome (SARS), starting in 2002 in China. There were 8,422 cases of SARS 
resulting in 916 deaths across 29 countries. SARS is caused by severe acute respiratory 
syndrome coronavirus (SARS-CoV-1). Ten years later, the middle eastern respiratory 
syndrome (MERS) outbreak started in Saudi Arabia. There were 2,494 cases of MERS resulting 
in 858 fatalities across 27 countries (19). 
The mortality rate of COVID-19 is variable (depending on factors such as comorbidities, 
availability of ICU, and age), but appears to be around 4% on average - making SARS-CoV-2 
the least deadly of the three mentioned human CoVs. However, because COVID-19 also has a 
less severe clinical picture, it can spread more easily than MERS and SARS. The sudden influx 
of patients requiring ventilatory support can overwhelm hospitals, resulting in a higher case 
fatality rate (such as 8.37% on 18.3.2020 in Italy) (18). 
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SARS, MERS, and COVID-19 are zoonoses - originating from bats and being transmitted to 
humans through intermediate hosts (palm civets for SARS, dromedary camels for MERS, and 
possibly pangolin for COVID-19). Even before the first identification of human infection in the 
1960s, different CoV strains had been isolated in turkeys, mice, cows, pigs, cats, and dogs. 
These animals are highly present in the human environment, and as we are unable to eradicate 
those viruses from their reservoir hosts, further cross-species transmission remains a constant 
risk. Furthermore, viruses constantly evolve to become more infectious or deadly. The ongoing 
COVID-19 pandemic poses a threat to such changes as the more people that get infected, the 
higher the chance of the virus’s adaptation to humans (20).  
Porcine epidemic diarrhea virus (PEDV) represents one of the major threats to the swine 
industry. The usage of multiple vaccines controlled the spread of PEDV until 2010, when 
outbreaks of new strains started occurring in North America, Europe, and Asia. New 
vaccinations have efficiently prevented further outbreaks, however, the emergence of new 
strains continues to be problematic and the possibility of cross-species transmission is a risk to 
human health (21). Though vaccination is a viable option to address the current COVID-19 
pandemic crisis, vaccine resistance may appear, and additional treatment strategies need to be 
considered. 
Transmissible gastroenteritis virus (TGEV) is a CoV that affects swine and causes severe 
diarrhea, vomiting, and dehydration. It can be fatal in up to 100% of piglets younger than two 
weeks. Piglets surviving the first week of infection can recover, although they are often 
underdeveloped and can spread the disease to uninfected swine. TGEV infection damages the 
small intestine, impairs intestinal mucosal immune response, and increases the risk of secondary 
infections (22). 
Feline infectious peritonitis virus (FIPV) is a mutated (virulent) form of the feline coronavirus 
causing the feline infectious peritonitis (FIP) - a progressive and typically fatal disease of 
domestic cats. FIP is the most common cause of disease in cats younger than 2 years of age. The 
earliest signs of a FIP infection are a progressively worsening malaise, cyclic fever, loss of 
appetite and weight, and a failure to grow. Subsequent signs depend on the form and organ 
distribution of the inflammation, with severe swelling of the abdomen being the most common 
trait (23). The 3CLpro of FIPV can act as a model for the development of new antiviral drugs 
against emerging CoV-induced diseases (24). 
1.2 THE BIOLOGICAL TARGET 
Proteases (known as peptidases or proteinases), are proteolytic enzymes. They digest proteins 
by catalyzing the hydrolysis of the peptide bonds. Proteases usually catalyze the hydrolysis of 
various proteins, however, some of them are specific for substrates with a certain sequence. The 
protease active site consists of a binding site, where temporary intermolecular bonds form with 
the substrate and the catalytic site that lowers the activation energy for the hydrolysis (25). 
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The mechanism of catalysis is either the activation of a water molecule, which hydrolyzes the 
peptide bond (one-step catalysis), or the covalent binding of a nucleophilic residue to the 
substrate (two-step catalysis). 3Cpro and 3CLpro use the two-step catalysis, in which the C-
terminal part of the protein is released with the binding, and the N-terminal part with the 
hydrolysis of the acyl-enzyme intermediate. The acid-base-nucleophile amino acid set involved 
in the mechanism is the catalytic triad (25). 
Proteases have a crucial role in viral replication and are important targets for the discovery of 
antiviral drugs. 3Cpro and 3CLpro are functionally analogous viral proteases characterized by a 
distinctive chymotrypsin-like fold, cysteine as the active site nucleophile, and a preference for 
Gln residue at the substrate P1 position (Schachter-Berger (26) nomenclature –Figure 1) in 
protein and synthetic oligopeptide substrates (2, 27). 
 
Figure 1: Schachter-Berger nomenclature (26) of protease substrate residues and the active site subpockets. Amino acid 
residues of the substrate (green) are numbered by their relative location to the scissile bond and the active site pockets (blue) 
are labelled correspondingly. 
1.2.1 3C PROTEASE OF PICORNAVIRUSES (3CPRO) 
Picornaviruses enter the cell by attaching to a specific membrane receptor. The viral capsid is 
destabilized during the attachment and the genetic material is released into the cytoplasm (25). 
Picornavirus genome is then translated into a single large polyprotein, which is processed into 
11-12 mature proteins. The polyprotein has three parts: it starts with the sequence of four 
structural proteins (1A-D) – viral capsid components, followed by two parts with seven 
nonstructural proteins, which participate in virus replication: 2A-C, and 3A-D (6). 
Of those proteins, 2A and 3C are picornavirus-encoded proteases, involved in the cleavage of 
the polyprotein into functional proteins. Although the first cleavage in EVs is done by 2A 
protease, the main viral protease in all picornaviruses is 3Cpro (6). The 2A protein can have 
specific functions and is not homologous among different picornaviruses, while the fold of 3Cpro 
is conserved among picornaviruses. (16). 
3Cpro degrades host cell transcription factors and thus obstructs the cell’s gene expression, 
transcription, protein synthesis, and its nucleocytoplasmic transport. Additionally, transcription 
is blocked by the degradation of the host cell DNA-dependent RNA polymerase. The cleavage 
of transcription and translation initiation factors induces apoptosis, which puts the 3Cpro in the 
central role in the virulence of picornaviruses (28). 
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When comparing the 3Cpro structures with representatives of other viruses of the Enterovirus 
genus to the EV68 3CPro, the root-mean-square deviation (RMSD) of superimposed α-carbon 
atomic positions are: 0.58 Å (HRV2-3Cpro; 170 Cα atoms), 0.64 Å (PV-3Cpro; 173 Cα atoms), 
0.81 Å (EV93-3Cpro; 159 Cα atoms), 0.74 Å (EV71; 174 Cα atoms), 2.04 Å (HAV-3Cpro; 166 
Cα atoms), and 1.93 Å (FMDV-3Cpro; 170 Cα atoms). The structural similarity of the EV68-
3Cpro to the corresponding enzymes of HRVs and other EVs suggests that EV68-3Cpro may be 
a good template for the optimization of broad-spectrum antiviral compounds for the treatment 
of picornavirus-induced diseases (5). 
1.2.2 3C-LIKE PROTEASE OF CORONAVIRUSES (3CLPRO) 
CoV genome encodes two polyproteins: pp1a and pp1ab. These two proteins are cleaved by the 
papain-like protease (PLpro) and the 3CLpro (aka the coronavirus main protease [Mpro]), to 
produce crucial proteins for viral replication. Coronavirus 3CLpro is a protease with an 
equivalent function and a similar structure to picornavirus 3Cpro. One of their notable differences 
is the catalytic Cys-His dyad of 3CLpro instead of a Cys-His-Asp/-Glu triad of 3Cpro (29).  
The sequence identity of the PLpro of SARS-CoV-1 and SARS-CoV-2 corresponds to the 
genomic at 83%, while SARS-CoV-1-3CLpro shares 96% sequence identity with its SARS-CoV-
2 counterpart. Replacement of Ala46 in SARS-CoV-1-3CLpro by Ser46 in SARS-CoV-2-3CLpro 
is the only difference proximate to the active site. Although this mutation replaces a lipophilic 
amino acid with a hydroxyl-containing one, it is not expected to significantly affect the binding 
of small molecule inhibitors (30). The RMSD between the SARS-CoV-2 and SARS-CoV-1 is 
0.53 Å for all Cα positions (31). The active sites of 3CL
pro of various CoVs also have a higher 
conservation of catalytic cores than their spike proteins or the PLpro (21). 
The cleavage in most CoV-3CLpro happens between the Leu-Gln combination on the N-terminal 
side and Ser, Ala, or Gly on the C-terminal side. No human proteases have a similar cleavage 
specificity, which lessens the potential toxicity of the inhibitors (31). 
1.3 3CPRO AND 3CLPRO BINDING SELECTIVITY AND INHIBITION 
Currently, several medicines targeting viral proteases are already available on the market for the 
treatment of human immunodeficiency virus and hepatitis C virus infections. Their discoveries 
represent a breakthrough in the management and treatment of these diseases (21). 
3Cpro inhibitors have shown antiviral activity against enteroviruses, coxsackieviruses, and 
rhinoviruses (29). Furthermore, several substances also exhibit inhibition of 3C/3CL proteases 
of different families within the picornavirus-like supercluster, giving a foundation for the 
development of broad-spectrum antivirals targeting both 3Cpro and 3CLpro (27). 
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1.3.1 PREVIOUSLY DEVELOPED INHIBITORS  
The cleavage of proteins by 3Cpro happens between the P1′-Gly and P1-Gln in PV (genus 
Enterovirus), and next to either P1-Gln or P1-Glu in FMDV (Aphthovirus) (28). The PEDV-
3CLpro cleaves the bond between a small aliphatic amino acid residue P1’-(Gly/Ala/Ser) and P1-
Gln with a hydrophobic residue at P2 (preferably Leu). P2-Met mutation only slightly reduces 
the cleavage efficacy, while P2-Ile and P2-Val still retain around 60% of the activity (21). Table 
I summarizes the residue recognition patterns of the 3Cpro of two enteroviruses (EV71 and 
CVA16) in comparison to a coronaviral SARS-CoV-1-3CLpro. 
Table I: Substrate specificity of the 3Cpro and 3CLpro of viruses in the picornavirus-like supercluster (2, 31). 
 P2' P1' P1 P2 P3 P4 P5 
EV71-3Cpro Pro Gly Gln Leu/Phe Val/Leu/Thr Ala Glu 
CVA16-3Cpro Pro Gly Gln Phe Leu Ala Glu 
SARS-CoV-1-3CLpro Gly Ala/Ser/Gly Gln Leu Val/Thr/Lys Ala Ser 
In general, 3Cpro and 3CLpro have a common point in the recognition of Gln at P1 substrate and 
a smaller lipophilic or an aromatic residue at P2. The S3 pocket is completely absent in 3Cpro, 
and the P3 position can employ various residues. However, a positive correlation between the 
size of an aliphatic residue in P3 and inhibitor cytotoxicity can be observed in some cases. The 
P4 position can only be occupied by small side chains. As the inhibitors often have larger groups, 
these occupy the same area as the substrate’s main-chain and partly protrude into S5 (5). 
The versatility of the P3 position has been exploited in the design of macrocyclic inhibitors by 
linking the P1-Gln to the P3 residue side chain, which can result in better cellular permeability, 
improved proteolytic stability, and reduced entropy loss upon binding. Development of such 
macrocyclic compounds has been first described by Mandadapu et al. (2), and the resulting 
aldehyde compound Inhibitor 8 (A on the Figure 2) has been tested on enteroviral 3Cpro, and 
caliciviral and coronaviral 3CLpro. The reported IC50 values are: 1.8 μM (CVB3-3C
pro), 5.1 μM 
(NV-3CLpro), and 15.5 μM (SARS-CoV-1-3CLpro). 
 
Figure 2: A Macrocyclic broad-spectrum Inhibitor 8 developed by Mandadapu et al. (2) has position P3 linked with the amide 
of position P1. B GC376 – 3Cpro and 3CLpro inhibitor with in vivo proven efficiency for the treatment of FIPV. 
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Broad-spectrum 3C/3CLpro inhibitors have already proved as effective in vivo. For example, 
GC376 (Figure 2 B) shows effects on the viruses belonging to the picornavirus-like supercluster 
in in vitro assays and leads to a recovery of cats suffering from an otherwise fatal disease caused 
by the FIPV. Biochemical assays on coronaviral 3CLpro yield an IC50 1.11 ± 0.13 µM for PEDV, 
0.82 ± 0.47 µM for TGEV, and 4.35 ± 0.47 µM for SARS-CoV-1 (21). The IC50 value for a 
representative of caliciviruses is 0.49 ± 0.05 µM for NV-3CLpro and for picornaviral 3Cpro the 
values are: 0.20 ± 0.14 µM for HRV, 1.77 ± 0.31 µM for PV, and 1.16 ± 0.75 µM for FMDV. 
GC376 does not inhibit the activity of HAV-3Cpro (27). 
Rupintrivir (A on Figure 3) and its analog AG7404 (B on Figure 3) are the only 3Cpro inhibitors 
that have reached clinical trials (28). These two substances most likely failed in clinical trials 
because the ethyl ester of the Michael acceptor warhead is hydrolyzed to an acid form upon 
administration (6). The resulting α,β-unsaturated acids are not Michael acceptors, and the 
metabolite cannot bind covalently to the active site nucleophile. 
 
Figure 3: Rupintrivir, previously known as AG7088 (A), its analog with improved oral bioavailability AG7404 (B), and a broad-
spectrum acting analog 3CLpro-1(C). 
Only a few molecules are known to inhibit SARS-CoV-1-3CLpro in the nanomolar range. Entry 
C in Figure 3 depicts one of the most potent reported inhibitors of SARS-CoV-1-3CLpro. Labeled 
as 3CLpro-1 in a recent review by Morse et al. (30), it has been reported as a promising 
candidate for the inhibition of SARS-CoV-2-3CLpro due to an exceptional similarity of the active 
sites of both enzymes. This compound has been originally developed as a rupintrivir analog with 
an improved inhibition of the EV71-3Cpro (IC50 < 0.5 µM and EC50 = 0.007 ± 0.001 µM; 
compound 10e (32)). While rupintrivir is inactive against SARS-CoV-1-3CLpro, the structural 
modifications made 3CLpro-1 a potent inhibitor of SARS-CoV-1-3CLpro, and MERS-CoV-
3CLpro (IC50 values of 0.2 ± 0.07 µM and 1.7 ± 0.3 µM respectively; compound 6d) (29).  
1.3.2 COMPOUND 3 (MLC3) AND ITS OPTIMIZATION 
The development of a new drug from the original idea to the product market access usually takes 
about 12-15 years and costs more than $1 billion. The first findings often originate from 
academia and provide the information on whether modification, activation, or inhibition of a 
biological molecule or a pathway results in physiological changes that can be used in the 
treatment or prevention of a disease (33). 
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This biomolecule (a receptor, enzyme, transporter, etc.), is labeled as the biological target and 
may require additional validation to justify the costs and effort of the drug discovery process. A 
good target is efficacious, safe and ‘druggable’ – the binding of a molecule to the target produces 
a biological response that can be measured in-vitro and in-vivo. The process proceeds with 
“identification” – the discovery of fragments or molecules binding to the biological target in the 
low (μM to mM) affinity range (33, 34). 
The indispensable role of 3Cpro and 3CLpro in the virus replication and its druggability have been 
well established and their inhibitors have been validated in vivo as antiviral targets – they can 
lead to a full recovery of otherwise lethal infections in animals (21). 
Compound 3 (renamed to MLC3 in this thesis) is a novel type of an irreversible EV68-3Cpro 
inhibitor with selective binding to the active site nucleophile (Cys147). The compound has been 
discovered by Yousef et al. (35) at the Freie Universität Berlin in 2019 by in silico evaluation 
and in-vitro assays of commercially available compounds containing substructures capable of 
producing a Meisenheimer complex intermediate upon reaction with the cysteine.  
Meisenheimer complexes (Figure 4) are anionic intermediates formed by covalent addition of a 
nucleophile to the electron-deficient aromatic or heteroaromatic ring. They are crucial 
intermediates in nucleophilic aromatic substitution (SNAr) reactions. Formation of 
Meisenheimer complex intermediates with cysteine residues has been previously applied in the 
development of covalent allosteric modulators of Class-B G protein-coupled receptors and 
kinase inhibitors. Compound 3 is the first reported cysteine protease inhibitor of such type (35). 
 
Figure 4: Meisenheimer complex (A) is an intermediate in nucleophilic aromatic substitution reactions. A 2-sulfonyl-pyrimidine 
moiety is shown as substrate example – analogous reactions can take place on other electron-deficient aromatic or 
heteroaromatic compounds, such as MLC3 formerly known as Compound 3 (B). 
MLC3 exhibits an apparent IC50 value of 16.6 ± 2.1 μM (35), leaving room for improvement. 
It can be regarded as a “hit” that needs optimization to a more potent and selective compound 
before entering preclinical studies. 
With a molecular weight of 267.31 Da, MLC3 is a small molecule that can be regarded as a 
fragment. The preliminary selection of compounds was done by screening through a validated 
pharmacophore composed of exclusive zones, a hydrogen bond donor feature in the S1 pocket, 
a hydrogen bond acceptor feature in the S1 pocket, and a hydrogen bond acceptor feature in the 
oxyanion hole (35). 
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An onefold binding to Cys147 was proven for MLC3 by protein mass spectrometry and tryptic 
digest of protein fragments. EV68-3Cpro has two surface-exposed cysteine residues, and the 
onefold binding gives the first information on the selectivity of the binding of the compound to 
the active site cysteine (35).  
2 MOTIVATION AND SCIENTIFIC GOAL 
Driven by the urgent need of antiviral medications for the treatment of picornavirus-induced 
diseases, the aim of the thesis is to optimize the binding of MLC3 (aka Compound 3), a novel 
covalent inhibitor of EV68-3Cpro, by simultaneously: 
1. Growing a molecule from the lead scaffold, i.e. using the fragment-growing approach 
in silico to propose derivatives forming additional interactions with the active site, 
2. Optimizing the scaffold, i.e. analyzing the structure-activity relationship (SAR) using 
commercially available structural analogs. The results can then be implemented by 
switching the scaffold from MLC3 to a more favorable analog. 
For the assessment of derivatives within the chemical space defined by the two necessary 
fragments in an appropriate spatial arrangement, the following questions will be considered: 
• Which standard (or reported) synthetic steps can be employed to obtain the derivatives? 
• To which functional groups (FG) can the derivatives be simplified? 
• To which extent do they have to be simplified so that the least chemical steps are needed, 
but still a diverse chemical space of the products is covered? 
These questions will be addressed using retrosynthetic analysis. The starting materials will be 
filtered and transformed (in silico “synthesized”) into end-products using KNIME (36). End 
products will be in silico evaluated for their 3Cpro inhibition potential by pharmacophore-based 
virtual screening (37) using LigandScout (38). Top results will be docked in the binding site 
using GOLD, energy-minimized using MMFF94 (39) (Szybki (40)), and reevaluated by the 
pharmacophore fit score and visual inspection.  
Following the emergence of the COVID-19 pandemic, we expanded the idea to explore the 
possibility of directing the optimization towards broad-spectrum (3Cpro and 3CLpro) inhibitors. 
This decision is based on two supporting arguments: 
• Development of broad-spectrum 3Cpro and 3CLpro inhibitors occupying multiple active 
site pockets is possible, as such results have already been reported in the literature, 
• One of the features connecting the 3Cpro to 3CLpro is the preservation of the preferred 
substrate P1 residue, and MLC3presumably occupies only the S1 pocket. 
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3 MATERIALS AND METHODS 
3.1 ALIGNMENT OF THE PROTEIN STRUCTURES (MOE) 
MOE (Molecular Operating Environment) is a drug discovery software platform developed by 
Chemical Computing Group Inc (41). MOE 2019.0102 was used for the visualization and 
preparation of protein structural data. 
Alignment of protein structures was performed using the MOE-integrated Sequence Editor. 
When different enzymes share similar substrates and inhibitors, the local similarity between 
their active sites is usually higher than their general structure. Therefore, whenever ligands were 
present in the enzyme structure, the superposition was limited to the pocket residues (around 
4.5 Å of the ligand) to improve the alignment results. This was done by changing the superpose 
setting in the Sequence Editor to Pocket Residues. 
3.2 RETROSYNTHESIS AND SYNTHESIS PLANNING 
Retrosynthetic analysis (or retrosynthesis) is a strategy used in the planning of organic synthesis. 
This is a backward analysis starting with the desired product (target molecule) and simplifies it 
to a precursor of lower or similar complexity. The reversal of a synthetic step is represented by 
the symbol ⇒. This step is repeated until the identification of a readily available starting 
material for which a synthetic route producing the target molecule can be developed (42). 
This is achieved by disconnections – the breaking of bonds represented by a wavy line 
perpendicular to the fragmented bond; and by functional group interconversions (FGI) – 
conversions of one FG into another. A disconnection results in two synthons, which can be either 
a pair of fragments bearing an opposite charge or two radicals. Synthons are usually very 
unstable and cannot be directly used for the synthesis. The actual reagents used for the forward 
synthesis are usually the synthetic equivalents of the synthons (42). 
A triple line can be used to connect a synthon to its synthetic equivalent. In this thesis, the 
synthons are usually omitted for simplification – the corresponding synthetic equivalent is 
placed in their place instead. 
3.3 IN SILICO SYNTHESIS OF DERIVATIVES (KNIME) 
KNIME Analytics Platform is open-source software for the creation and visual representation 
of ordered data transformation operations that can be concurrently performed on large amounts 
of data. The visual representation is named a workflow, while the single data processing 
operation units are nodes. A node can modify, transform, model, or visualize the data (36).  
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KNIME 4.1.2 was used to produce a workflow leading to a file containing structural data of 
derivatives obtainable by the chemical transformation of commercially available starting 
compounds. The steps performed with KNIME were: 
• The generation of a library of commercially available compounds from three sources 
(ChemDiv Chemistry Building Blocks, Enamine Building Blocks, and MolPort), 
• the collection of the starting compounds containing substructures determined by the 
retrosynthetic analysis, 
• the transformation of the starting compounds to the products (in silico derivative 
synthesis), 
• the elimination of products containing reactive moieties like epoxides and multiple 
entries of the same molecule (duplicates) 
• the production of enantiomers in the newly formed bonds 
A workflow starts with a node that imports the data from a file to the platform (such as the File 
Reader node). The imported data is then stored in an internal format represented by a table with 
columns containing the data (a string, molecule, etc.). These data tables can be saved as a file 
using the Table Writer node and later imported into another workflow with the Table Read 
node. Within the same workflow, the data is sent from one node to another by connections 
(visually represented by wires) from the node output and input ports. Nodes first process the 
entire input table before sending the results to successor nodes (36).  
Workflow processes can be executed repeatedly by using the Recursive Loop Start and 
Recursive Loop End nodes. The data passed to the upper input port of the Recursive Loop End 
is collected for the output, and the data in the lower is returned to the Recursive Loop Start. 
Columns from different dataflows or sources can be concatenated using the Concatenate node. 
The concatenated columns must be named identically in each input table. The node GroupBy 
can create a row for each unique value within the selected input column. Values from the 
remaining columns can be collected based on the specified settings. 
Various nodes can be used for writing out the data of the workflow, depending on the type of 
the data processed and the desired output format. For example, CSV Writer can be used to write 
out a comma-separated values file (“.csv”) or a text file (“.txt”). A text file consisting of a 
different SMILES value in every row can be converted to SMILES using the text editor. 
RDKit nodes are community nodes developed in collaboration with KNIME that allow 
chemical data processing within the KNIME platform. RDKit uses an internal format that can 
be generated from the typical molecule representations (SDF, SMILES, or SMARTS) by the 
RDKit From Molecule node. After the desired data processing has been done, they can be 
transformed back to one of the typical molecule representations with the RDKit To Molecule 
node. Canonical SMILES can be produced using the RDKit Canon SMILES to avoid different 
SMILES representations of the same molecule and to eliminate duplicates with the GroupBy. 
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RDKit Substructure filter allows the collection of molecules containing a user inserted 
structural pattern in the upper output port, and the molecules not containing the substructure in 
the lower output port. RDKit Functional Group Filter has the same functionality by offering a 
table where the presence or absence of FGs can be selected in the provided configurations table. 
Structural modification of the input molecules can be achieved using the RDKit One 
Component Reaction. These three nodes function by the utilization of SMARTS patterns. 
SMARTS (43) is a language for describing molecular patterns used for the search of a specific 
molecular substructure. Rules for SMARTS are straightforward extensions of SMILES, and 
almost all SMILES syntax are valid expressions in SMARTS. The same atomic and bond 
symbols are used as in SMILES to define a molecule, but these are extended to include logical 
operators and various atom and bond properties (43). 
The RDKit One Component Reaction uses reaction SMARTS, an extension of SMARTS that 
is somewhat different from SMIRKS (a language designed specifically for reactions) (44). The 
general structure of a reaction SMARTS is “ reactants >> products ”. The reactants are given as 
queries of the substructure connected to the transformation. If there are more such substructures 
in the reactant molecule, the match can be generated for any of them. In reaction SMARTS 
atoms are mapped using the expressions of form [A:N], where A is the SMARTS atom 
description and N is a map class value. In this way, the language can link the changes made to 
a specific atom within the structure. For example, if a specific carbon atom [C:1] gets replaced 
by a nitrogen atom during the reaction, the change is linked by the map value of the nitrogen 
atom in the product molecule [N:1]. A dot is used to separate chemicals when multiple structures 
need to be considered (e.g. for the output of both products). Brackets can be used to indicate 
that the transformation is intramolecular (43, 44). 
3.4 PHARMACOPHORE OPTIMIZATION AND VIRTUAL SCREENING 
(LIGANDSCOUT) 
A 3D pharmacophore (a pharmacophore model) is a spatially organized combination of 
necessary steric and electronic features for the intermolecular interactions of a ligand with the 
biological target and thus its biological activity (45). Pharmacophores can be developed either 
by analysis of the known receptor-ligand complex (structure-based design) or from a set of 
ligands with a similar binding mechanism (ligand-based design) (38). 
Virtual screening is the process of evaluating extensive sets of compounds (compound libraries) 
for the desired biological activity. Structure-based design is traditionally linked to screening by 
docking: first, the pose of the molecule in the binding site is determined, then the binding is 
rated by various scoring functions. Pharmacophore-based virtual screening has a clear benefit 
over docking in being less computing-intense and that it does not force the production of a result 
(a conformer either fits the given pharmacophore or it does not) (38). 
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In this thesis, pharmacophore-based screening was used as a pre-selection procedure to narrow 
the number of molecules that needed to be docked. Before the pharmacophore-based virtual 
screening could be performed, an appropriate pharmacophore had to be generated. LigandScout 
4.4.3 was used for the optimization of the pharmacophore, just as well as for the pharmacophore-
based virtual screening purpose. LigandScout is a software allowing fast production of three-
dimensional pharmacophores from the receptor-ligand complex structure (38). 
The creation and validation of the pharmacophore that led to the discovery of MLC3 (45.pml) 
preceded this master’s thesis and was done within the same workgroup by Yousef et al. (35) 
using PyRod. PyRod (46) is a software for the identification of possible macromolecule-ligand 
interactions, their visualization as pharmacophoric features, and the subsequent creation of 
pharmacophores. This is done by the analysis of the water molecules in the protein environment, 
using MD simulations. An extensive set of pharmacophores was created by combining the 
possible enzyme-inhibitor interactions proposed by PyRod. Yousef et al. (35) used a combined 
set of inhibitors with reported activity against the 3Cpro and decoys created by the DUD-E 
(Database of Useful Decoys- Enhanced) (47) to validate the pharmacophores. The 45th 
pharmacophore in the set (45.pml) happened to provide the best results. 
Two EV68-3Cpro structures, the first one containing the docked MLC3, and the second 
containing its ethyl-linked analog (ELC3), were aligned to a molecular dynamics (MD) 
simulation snapshot of an EV68-3Cpro. The conformation of this PyRod-retrieved EV68-3Cpro 
structure corresponded to the interactions formed by the 45.pml pharmacophore. By aligning 
the three protein structures, docked MLC3 and ELC3 poses could be placed in the binding site 
along with the 45.pml pharmacophore features for the pharmacophore optimization. 
After the in silico synthesis of MLC3 and ELC3 derivatives, CORINA 3.00 (48) was used on 
the KNIME output file for the conversion of the SMILES strings into a 3D representation of 
molecules in SDF format. Option “mdlcompact” was used to save disk space by generating 
compact SDFiles, which contain only mandatory data for 3D structure information. 
LigandScout command line tool idbgen was used for the preparation of the conformer library 
(LDB) of the derivatives for virtual screening. The conformations were generated using the iCon 
high-quality settings that generated up to 200 conformers for every derivative. Pharmacophore-
based virtual screening of the conformers was done using the LigandScout tool iscreen. 
3.5 DOCKING AND ENERGY MINIMIZATION (GOLD, SZYBKI) 
Molecular docking is a computational method for the prediction of the pose (conformation and 
orientation) of a ligand in the binding site of a macromolecule. The program GOLD 5.8.1 (49) 
has been used to dock the hits of the pharmacophore-based virtual screening. The docked 
derivatives have been energy-minimized in the EV68-3Cpro active site by SZYBKI 1.8.0.1. (40) 
using the exact analytical Van der Waals potential and exact Coulomb potential. 
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3.6 STRUCTURE-ACTIVITY RELATIONSHIP 
Structural analogs were found by using the Tanimoto similarity search in Enamine Real Space 
based on Morgan 2 fingerprint, 512 bit (https://enamine.net/library-synthesis/real-
compounds/real-compound-libraries), N-substituted structures were discarded to preserve the 
interactions within the S1 pocket.  
4 RESULTS AND DISCUSSION 
4.1 MLC3 BINDING MODE AND OPTIMIZATION RATIONALE 
Amino acid substitution study of Coxsackievirus B3 3Cpro, an enzyme structurally similar to the 
EV68-3Cpro (RMSD of 0.78 Å for 173 Cα (5)), revealed that mutations at Thr142, His161, 
Gly164, Gly169, or Ala172 abolished the activity of the enzyme (50). Thr142, His161, and 
Gly163 are also the major amino acids of poliovirus 3Cpro substrate recognition (51). MLC3 is 
believed to occupy the area in the S1 pocket proximate to these residues. Figure 5 shows the 
non-covalent interactions between the docked MLC3 and the EV68-3Cpro active site. 
 
Figure 5: Non-covalent interactions between EV68-3Cpro and MLC3 as suggested by docking. 
The 3Cpro-substrate interface primarily involves the S4-S2’pockets, with the most important 
interactions formed within the S1, the S2, and the S4 pockets (52). The MLC3 exhibits an IC50 
of 16.6 ± 2.1 μM (35) by occupying the S1 pocket alone. In comparison, the combination of the 
key moieties of the peptidomimetic covalent inhibitors is not sufficient for activity (P1-lactam, 
P2-phenyl Michael acceptor-type inhibitor exhibits no EV71-3Cpro inhibition at 20 μM) (32). 
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MLC3 shows activity in the micromolar range by only occupying a fraction of the area in the 
active site that is usually occupied by known inhibitors and shows higher activity than the 
corresponding fragments in their structure. This gives good ground to fragment growing, the 
first approach to the optimization of MLC3. Fragment growing is the structural expansion of a 
small ligand by the addition of substituents that contribute to the binding affinity by forming 
favorable interactions with the unoccupied pockets of the binding site while retaining the 
original interactions of the ligand (34). The resulting molecules are the derivatives of the 
original ligand. 
The second approach is the structure-activity relationship analysis – researching the activity 
of commercially available compounds that are MLC3-like but contain subtle differences in their 
structure (structural analogs, or simply analogs). These two techniques can complement each 
other - a structural analog might provide better inhibitory activity on 3Cpro and derivatives of 
that analog can be formed instead of the ones containing the MLC3 parent structure. 
The terms derivative and analog are generally considered synonymous in drug design. To 
distinguish the fragment-grown molecules from the MLC3-like molecules found in the catalogs 
of commercially available substances, the terms are used distinctly in this thesis. The two 
approaches of optimization are performed separately at this stage and they focus on different 
parts of MLC3.  
The structure of MLC3 can be split into four parts. The first part is the covalent warhead (5-
methyl-pyrimidin-2-yl sulfone) binding to the cysteine (Cys147) in the active site. The second 
is the 1H-1,2,4-triazole (or simply triazole, unless otherwise specified), which is necessary for 
the S1 pocket interactions. The warhead and the triazole are connected by a chemical “linker”. 
In the structure of the MLC3, the linker is a simple carbon atom (α-carbon relative to the 
sulfone). The last part is the ethyl-tail, an ethyl substituent occupying the 5-position of the 
triazole. 
 
Figure 6: The structure of MLC3 can be divided into 4 parts. The warhead region covalently binds to the active site nucleophile 
(Cys147). The 1,2,4-triazole forms crucial interactions for selectivity and affinity towards the active site. In the structure of 
MLC3, the former two parts are linked by an aliphatic α-carbon (relative to the sulfone). The ethyl-tail forms no explicit 
interactions with the active site. 
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4.1.1 THE COVALENT WARHEAD 
The warhead (5-methylpyrimidin-2-yl sulfone) is responsible for the irreversible inhibition of 
EV683Cpro by covalent reaction with the active site nucleophile (Cys147). The reaction 
mechanism is nucleophilic aromatic substitution (Figure 7). The 5-methyl group of the warhead 
is not involved in the reaction mechanism and can likely be substituted. 
 
Figure 7: The mechanism of inhibition involves the reaction between the electrophilic center of the warhead (2-carbon of 
pyrimidin-2-yl sulfone) and the active site nucleophile (Cys147). 
By mass spectrometry analysis of the trypsin-digested EV68-3Cpro, Yousef et al. (35) have 
proven the covalent mechanism of inhibition and the selectivity of the binding of MLC3 to the 
active site nucleophile (Cys147). In the determination of the MLC3 binding mode, it needs to 
be considered that the electrophilic center of the warhead (2-carbon of pyrimidine-2-yl sulfone), 
needs to be proximate to the Cys147 for the reaction to proceed and the compound to be active. 
Pyrimidine-2-yl sulfone is not the only heteroaryl sulfone moiety that can be a potential 
substrate for nucleophilic aromatic substitution. Figure 8 shows some of the other πelectron-
deficient heterocycles that allow comparable chemical reactivity and could replace the 
pyrimidine. These are common reagents in organic synthesis for the preparation of carbon-
carbon double bonds from carbonyl compounds through modified Julia olefination (53). 
    
Benzothiazol-2-yl 1-phenyl-1H-tetrazol-5-yl Pyrid-2-yl 3,5-bis(trifluoromethyl) phenyl 
Figure 8: Examples of other π-electron-deficient (hetero)aromatic moieties 
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4.1.2 THE TRIAZOLE MOIETY 
The enzyme-inhibitor complex structures (5), as well as mutational studies (50) show that the 
S1 pocket interactions with Thr142 and His161 are crucial for the recognition of the substrate 
and the inhibitors by the 3Cpro. MLC3 displays observable inhibition of the EV68-3Cpro and an 
active-site-specific covalent binding to the Cys147, therefore it must be recognized by the S1 
pocket. 
3Cpro proteases are generally specific for P1-Gln (54). In the EV68-3Cpro enzyme-inhibitor 
complex crystal structures (3ZV9, 3ZVA, 3ZVB, 3ZVC, 3ZVD, 3ZVE, 3ZVF, 3ZVG) (5), a γ-
lactam ring replaces the amide FG of the glutamine in the P1 position, as the reduction of the 
conformational entropy loss upon binding of the lactam leads to a higher binding affinity. The 
lactam moiety donates a hydrogen bond from the lactam nitrogen either towards the main chain 
carbonyl (mcCO) of Thr142 or a water molecule and accepts two hydrogen bonds with the 
lactam oxygen atom – one from the Oγ of Thr142 and the other from the His161 (5). 
The triazole is a novel feature of the MLC3 as a 3Cpro inhibitor. Although the triazole is an 
amide bioisostere, it might not allow the same hydrogen bonding within the S1 pocket as an 
amide FG. The distance between the hydrogen bond acceptor and the hydrogen bond donor 
nitrogen atoms within the rigid triazole ring is constant, yet it might be too narrow to allow 
concurrent interactions of the triazole with both His161 and the mcCO of Thr142. 
The carbonyl oxygen atom belonging to the amide FG bears a double lone pair of electrons and 
can act as a double hydrogen bond acceptor. Each of the three nitrogen atoms forming the 
triazole can only form one hydrogen bond – the nitrogen bearing a hydrogen atom can donate, 
while the other two can each accept a single hydrogen bond. Triazole exists in three tautomeric 
forms (Figure 9). 
 
Figure 9: Triazole exists in an equilibrium of three tautomers. In the predominant and most favorable form hydrogen is attached 
to the nitrogen with the highest electron density:  (R2 more electron-donating) or  (R1 more electron-donating). 
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The predominant 3,5-disubstituted triazole tautomer has its hydrogen at position 1 or 2 – the 
one that is closer to a more electron-donating substituent (55). If the active tautomer is the less 
stable one, then based on the rate of tautomer interconversion the following occurs: 
• if the rate of tautomer interconversion is slower than the inhibitor binding kinetics, 
activity is dependent only on the concentration of the active tautomer species. 
• if the rate of tautomer interconversion is faster than the binding kinetics, the rate of 
interaction is still dependent on the concentration of the active tautomer, but the 
complete amount of the inhibitor can eventually bind to the enzyme (56). 
Docked poses of the predominant MLC3 tautomer were used to observe the placement of the 
triazole moiety in the S1 pocket. Two binding hypotheses were proposed by docking (Figure 
10). MLC3 was discovered by fitting in the binding hypothesis 1, where the triazole donates a 
hydrogen bond to the mcCO of the Thr142 and accepts a hydrogen bond from its Oγ FG.  
 
Figure 10; The docking of MLC3 (green carbon atoms) suggests two binding modes. The triazole either interacts with the Oγ 
of Thr142 and the mcCO of Thr142; or the Oγ of Thr142 and His161. 
The second binding hypothesis involves the hydrogen bonding interactions with His161 and the 
Oγ of Thr142. While only one tautomeric structure can be active in the binding hypothesis 1, all 
three tautomeric forms can potentially be active by forming hydrogen bond interactions between 
the same atoms involved in the binding hypothesis 2 (Figure 11). 
 
Figure 11: The three tautomers of the MLC3 triazole can form the same hydrogen bond interactions with the two residues 
because the Thr142 side chain can either donate or accept the hydrogen bond, and because His161 has two tautomeric forms. 
His161 




The binding of the N4 of the 1,2,4-triazole to the S1 pocket appears to be prevented by the steric 
hindrance of the ethyl-tail. The other two nitrogen atoms, N1 and N2, can each be involved in a 
maximum of one hydrogen bond interaction with the enzyme. Both binding hypotheses from 
docking preserve two of the three enzyme-inhibitor interactions in the S1 pocket that can be 
seen in the crystal structures (5) and are formed with the residues that are crucial for the substrate 
recognition (50). 
The third binding hypothesis involves a hydrogen bond acceptor interaction with His161 and a 
hydrogen bond donor interaction with the mcCO of Thr142. This interaction is not predicted by 
docking since the distance between nitrogen atoms of the triazole are fixed and a rigid enzyme 
structure was used for the docking. In all the available structures of the enzyme (ligand-bound 
crystal structure, ligand-free crystal structure, or snapshots from MD), an oxygen atom stabilizes 
a hydrogen bond bridge [His161]H--O--HO[Thr142]. In the ligand-bound structures, the oxygen 
comes from the lactam moiety and in the ligand-free structures, it comes from a water molecule. 
A receptor structure stabilized in this manner does not allow the formation of the binding 
hypothesis 3. 
Authors of all the available EV68-3Cpro crystal structures report that the length of the hydrogen 
bond formed with His161 remained constant (2.8 Å) in crystal structures involving different 
inhibitors, which suggests a stable and conserved interaction with His161 (5). Structure-activity 
relationship studies suggest that the carbonyl oxygen making H-bonds to Nε2 of His-161 and 
Oγ of Thr-142 is important for potency (P1 dimethyl amide and ketone analogues preserve 
activity) (57). If considering broad-spectrum activity – in at least one coronaviral 3CLpro 
structure (SARS-CoV-1-3CLpro; PBD ID: 3V3M (58)), only a single hydrogen bond can be 
formed by the pyrimidine in the S1 pocket – with the corresponding histidine of SARS-CoV-1 
(His163). 
The mutational analysis of the substrate-binding site of 3Cpro of Coxsackievirus B3 (RMSD of 
0.78 Å for 173 Cα (5)), Thr142 to Ser142 mutation preserved the activity of the enzyme, while 
a Thrl42 to Leu142 abolished it (50) – the results either show that the Oγ of Thr142 is more 
important for the binding than its mcCO, or that a slightly bulkier Ile residue sterically hindered 
the substrate from binding. The enzymatic activity is lost when the His161 is replaced (50).  
Macrocyclic inhibitors forming interactions with His161 and the Oγ of Thr142 (but not the 
mcCO in the S1 pocket were found to be the most potent (IC50 = 0.002 μM) in the set of 
inhibitors when tested on HRV2-3Cpro (59). The results show that high-affinity inhibitors 
lacking the hydrogen bond donor towards the mcCO of Thr142 can be developed. 
Even though the MLC3 was discovered in the binding hypothesis 1 binding mode and would 
not fit the pharmacophore in the binding hypothesis 2, SAR studies, the structure of certain 
inhibitors and mutational studies support the binding hypothesis 2. 
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4.1.3 THE ETHYL-TAIL 
The ethyl-tail forms no interactions with the active site and is represented by a dashed line 
henceforth, indicating its substitution with a more hydrophilic moiety is likely beneficial. 
Substitution with an amine FG (3-Amino-1,2,4-triazole) might enable hydrogen bond 
interactions with the mcCO of Gly164 or Thr142. 
Macrocyclic inhibitors are mentioned to have an improved affinity to the 3Cpro than the standard 
Michael-acceptor peptidomimetic inhibitors and exhibit a broad-spectrum activity (2). There 
might be a possibility of a formation of a macrocyclic ring from this region. 
4.1.4 THE LINKER AND MLC3 DERIVATIVES 
The PDB contains 8 inhibitor-bound crystal structures of EV68-3Cpro. All structures originate 
from the same study (5) and contain the same “main scaffold” including a γ-lactam (S1 pocket) 
and an α,β-unsaturated ester (warhead). 
 
Figure 12: Inhibitor 85, the most potent inhibitor of EV68-3Cpro with a crystal structure in the PDB (code: 3ZVF (5)). The 
“common scaffold” (red) was not altered in any inhibitor and encompasses the same area in the active site as MLC3 
When comparing the crystal poses of inhibitors to the docked MLC3 (superposed by the enzyme 
structure), the α-carbon emerges as a reasonable position for substitution (Figure 13). 
 
Figure 13: Docked and energy minimized MLC3 (both binding hypotheses; green carbon atoms) placed in the active site of 





Preliminary pharmacophore-based screenings of the resulting MLC3 derivatives have been 
largely unsuccessful because the substituents have sterically hindered the binding of the MLC3 
scaffold. Considering only rotation was possible at the alpha position, the lack of internal 
flexibility within the MLC3 scaffold resulted in its displacement, and the original S1 pocket 
interactions were obstructed. 
Due to the non-regioselective nature of some of the triazole syntheses, every amide, acyl halide, 
and ester FG in the starting material was transformed into a triazole. As a result, this moiety was 
frequently found in the substituent part of the product molecules. One of the products containing 
two triazole rings (Figure 14) led to a surprising discovery by being placed in the S1 pocket 
through the substituent triazole moiety that was prolongated by an extra carbon in the linker. 
 
Figure 14: The product that was the foundation for the design of ethyl-linked derivatives. 
Extending the “linker” between the warhead and the triazole could enable substitution at the 
alpha position while rotation at the beta position could preserve the interactions within the S1 
pocket. To determine the optimal chain length between the sulfone and the triazole, we 
extrapolated the change and included propyl-linked derivatives to the set. However, none of the 
hits of the preliminary screenings were propyl-linked, and the propyl-linked derivatives were 
not considered for the optimization. 
The set was not changed onto a new scaffold but only updated and enriched by the addition of 
ethyl-linked derivatives. In other words, both the original “methyl-linked” Compound 3 
(MLC3) scaffold and ethyl-linked Compound 3 (ELC3) scaffold derivatives were created and 
screened under the same conditions.  
 
Figure 15: Poses of the MLC3 and the ELC3 in the EV68-3Cpro active site as proposed by the binding hypothesis 1 (left) and 
the binding hypothesis 2 (right). 
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4.2 RETROSYNTHESIS AND SYNTHESIS PLANNING 
The main novel feature of MLC3 is inhibition through formation of a Meisenheimer complex 
intermediate, which is formed by the warhead structure. Considering the proposed mechanism 
of inhibition (Chapter 1.3.2), the sulfone group substituted with an electron-poor aromatic ring 
is crucial and needs to be preserved during the optimization. Due to its importance for inhibition, 
the sulfide is placed in the center of the synthesis planning. It could be replaced by a sulfoxide, 
however, there is no explicit need for this change at this point as it would create an additional 
chiral center, which means screening twice as many molecules in silico and stereoisomer 
separation efforts. Moreover, sulfoxide analogs show less reactivity towards nucleophiles and 
the change might be detrimental to the irreversible mode of action (60). 
 
 
Figure 16: MLC3 and ELC3 represent core structures (scaffolds). When any of the hydrogens at R1-R4 positions is substituted, 
the resulting compound counts as an MLC3 or ELC3 derivative. Henceforth only one substituent (R) on the α-carbon is 
displayed for higher clarity - such derivatives are also expected to exhibit the highest activity. 
Two retrosynthetic options arise for the synthesis of derivatives when considering the sulfone 
FG. In the first option (complete synthesis), the derivative is synthesized concurrently with its 
MLC3 or ELC3 scaffold. The second option (sulfonyl carbanion reactions) starts with already 
synthesized unsubstituted MLC3 or ELC3 scaffold (Figure 16; R1-R4=H) and creates the 
derivative by a formation of α-sulfonyl carbanion that reacts with an electrophilic moiety. 
“Complete” syntheses (Chapter 4.2.1) result in a higher chemical variety of derivatives but have 
a high probability of side reactions, lower yields and cannot be applied to all MLC3 analogues. 
Sulfonyl carbanion reactions (Chapter 4.2.2) are more universal as they are linked only to the 
crucial sulfone group and can still be employed if SAR analysis provides a better scaffold. 
Multiple synthetic routes leading to the same derivative are possible for a single starting 
material. The final choice of the synthetic route is dependent on the specific substituent and 
resources (oxidation/reduction sensitivity, expenses, reactivity with reagents, lab equipment, 
temperature stability, side reactions, etc.). 
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4.2.1 COMPLETE SYNTHESIS 
The three most important methods of sulfone synthesis are: alkylation of sulfinate salts 
(nucleophilic substitution), reactions of sulfonic acid derivatives (electrophilic substitution), and 
oxidation of sulfides. Direct introduction of sulfur at a higher oxidation state is usually lower 
yielding than sulfide oxidation (61). 
4.2.1.1 Sulfone synthesis by sulfinate anion alkylation 
 
Figure 17: The first option of sulfone synthesis is alkylation of a sulfinate anion. The most used (and widely available) alkylating 
agents are alkyl halides (Scaffold 1a). 
A benefit of this pathway in comparison with the oxidation of thioethers is its applicability in 
cases where the substituent is sensitive to oxidation. However, sulfinate salts are less 
nucleophilic than thiolates and are ambident nucleophiles - the electrophilicity of the alkylating 
agent determines if the major produce is a sulfone (Product A on Figure 18)) or a sulfinate ester 
(Product B on Figure 18) (61). Although reactions between sulfinate salts and secondary halides 
with poor yields have been reported, they proceed under high temperatures which the warhead 
is unlikely to withstand, raising doubt over practical applicability of this route (62). 
 
Figure 18: Thiolates are ambident nucleophiles – they can react with either the sulfur or the oxygen. The first option is typical 
for weak electrophiles and produces sulfones (Product A), the second usually occurs with strong electrophiles and produces 
sulfinate esters (Product B). 
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4.2.1.2 Sulfone synthesis by reactions of sulfonic acid derivatives 
 
Figure 19: The second option of sulfone production are reactions involving sulfonic acid derivatives such as sulfonyl halides  
Syntheses of alkyl aryl sulfones from alkane-sulfonyl chlorides are frequently associated with 
side reactions, such as arene halogenation (61). Organometallic reagents might also react with 
the warhead. These reagents are produced from haloalkanes, so this route has the same precursor 
as the sulfinate anion alkylation retrosynthetic step (Scaffold 1a Figure 20). 
4.2.1.3 Sulfone synthesis by oxidation of sulfides 
Addition of a thiolate and subsequent oxidation of the generated thioether is considered the most 
useful and broadly applicable method, even though it involves an additional step when 
compared to the former two strategies. Oxidation of sulfides can be performed with a large 
selection of reagents, the most often used is meta-chloroperoxybenzoic acid (mCPBA) (61). 
Most oxidations are non-selective, however a controlled and selective sulfoxidation has been 
reported using a molybdenum based metallomicellar catalyst. This method tolerates several 
sensitive FGs (acetal, aldehyde, amine, imine, oxime, nitriles, and alkene) (63). 
 
Figure 20: Oxidation of thioethers is the most common method of sulfone synthesis. 
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Two types of precursors are possible for the thioether introduction: Scaffold 1a and Scaffold 1b 
(Figure 20). Analogously, starting with sulfonic acid derivatives or sulfinates could be suggested 
for previous pathways – this was avoided since they are rare and would have to be obtained by 
oxidation of Scaffold 1b. 
Even when disregarding the ethyl-tail requirement, few reactants containing Scaffold 1 (joint 
name combining Scaffold 1a and Scaffold 1b) substructure were found in the commercially 
available compound libraries. Further retrosynthetic steps were needed to obtain enough 
reactants and chemically diverse substituents. 
The biggest challenge of the “complete” synthesis pathways is therefore not the sulfone 
synthesis but synthesis of the triazole ring. Because of the unavailability of Scaffold 1 precursor 
compounds, retrosynthetic analysis must be continued for the 1,2,4-triazole synthesis pathway 
proposal. Triazole synthesis usually takes part under harsh conditions or includes nonselective 
reactions. This results in more side reactions, lower yields, and changes to the substituent region 
that cannot be easily predicted or generalized for computational structure modification (“in 
silico reaction”). 
On the other side, these syntheses are valuable mainly for three reasons: 
• In ELC3 derivatives, these routes can result in products containing a substituted β-
carbon. In that way they offer a higher chemical variability that is not directly accessible 
by sulfonyl carbanion reactions. 
• The sulfonyl carbanion reactions start with the unsubstituted MLC3 or ELC3 scaffold. 
These synthetic routes are therefore needed for the scaffold synthesis, unless these are 
available, affordable and purchased. 
• They can provide derivatives that differ in the ethyl-tail region. 
Scaffold 1 is from now on shown in solid squares, indicating that it is the connecting point of 
the sulfone and the triazole synthesis pathways. The results of the retrosynthetic analysis 
(derivative synthesis starting materials) are shown in dashed squares. 
 




4.2.1.4 1,2,4-triazole synthesis by Pellizzari reaction 
 
Figure 22: Retrosynthetic analysis of Scaffold 1. Proposed starting compounds for derivative synthesis by Pellizzari reaction 
are shown in dashed squares - only a single simple derivative could be obtained from using hydrazides as starting materials. 
During the Pellizzari reaction, nucleophilic substitution and elimination would co-occur at the 
site of the halogen, lowering yields. Previous research by Plesniak et al. (60) has shown that the 
π-deficient aromatic compounds react at the electrophilic center when it is connected to a 
sulfone, but not when connected to a thioether or sulfoxide FG. The unoxidized version of the 
warhead is less likely to react with nucleophiles in the reaction mixture. That way a better 
nucleophile (meaning better yields) and a worse leaving group (less susceptible to substitution) 
is introduced first and turned into a more reactive species by oxidation in the last synthetic step. 
In the literature it has been reported that treatment of brominated esters with pyrimidine-2-thiol 
in a suspension of sodium hydride in dimethylformamide (DMF) gives sulfides in excellent 
yields and later oxidation with mCPBA gives the corresponding sulfones (64). 
 
Figure 23:Derivative synthesis by Pellizzari reaction. To reduce unwanted side reactions at the halogenated aliphatic carbon 
and the warhead, the suggested order is: (1) preparation of the thioether, (2) triazole synthesis, and (3) oxidation to sulfone. 
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The standard method of hydrazide synthesis is hydrazinolysis of esters in alcoholic solutions. 
Zhang et al. (2002) describe another method under mild conditions with excellent yields using 
carboxylic acids. This method is suitable for α,β-unsaturated acids, preserves stereoisomers at 
the α-position and tolerates any esters and carbamates in the substituent part (65). 
Pellizzari reaction involves hydrazides and amides, and usually takes place at temperatures 
higher than 250°C. Especially with aliphatic hydrazides, transamination may occur between 
reactants, resulting in a mixture of triazoles and lower yields (66, 67). 
4.2.1.5 1,2,4-triazole by Einhorn-Brunner Synthesis 
 
Figure 24: Einhorn-Brunner reaction produces 1,2,4-triazoles from imides. Imides can be obtained from secondary amides, 
and those are accessible from a reaction between an amine and acyl chloride. 
In the Einhorn-Brunner reaction, imides react with semicarbazide in a boiling aqueous solution 
of sodium acetate over 15 h (68). The N-carbamoyl group in the intermediate reacts with the 
excess semicarbazide at the electrophilic carbonyl carbon and gets eliminated, producing a 3,5-
disubstituted 1,2,4-triazole (67). Imides can be easily obtained from secondary amides by 
oxidation with Dess–Martin periodinane in fluorobenzene and dimethyl sulfoxide (DMSO) at 




Acyl chlorides are one of the easiest and most economical reactants in secondary amide 
synthesis. Zhang et al. (2009) have proposed to perform the reaction in tetrahydrofuran (THF) 
with 2.5 equivalents of K3PO4. This minimizes hydrolysis, racemization and other side reactions 
while offering good to excellent yields with various substrates (70). 
 
Figure 25: The general proposal of derivative synthesis using the Einhorn-Brunner reaction. 
4.2.1.6 1,2,4-triazole synthesis from nitriles (3B) 
 
Figure 26: Several synthetic routes for the transformation of nitriles to triazoles have been reported. Two options are reaction 
with hydrazides under microwave irradiation (A) or copper-catalyzed oxidative coupling reaction with amidines (B). 
Yeung et al. (2005) report a base-catalyzed, direct synthesis of 3,5-disubstituted 1,2,4-triazoles 
from nitriles and hydrazides (pathway A on Figure 26). 3 equivalents of the nitriles and 0.1 
equivalents of K2CO3 resulted in the highest yield (84%) (71). 
When fully aliphatic reactants were used, the yields were lower. An aliphatic nitrile produced 
only modest yields (34%) and stirring it in a sealed tube at 150°C in an oil bath without 
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irradiation resulted in somewhat higher yields (42%). The lower yields of aliphatic reactants 
might reflect the fact that the reaction conditions were optimized using aromatic reactants (71). 
The yield of the reaction was only 14% when acetic hydrazide was reacted with benzonitrile. 
However, if the acetic hydrazide was substituted with a thiophene, it provided products in 
moderate yields. The yield of one such product, which especially resembled the MLC3, was 
62% (Figure 27) (71). Despite the resemblance in the product structure, it might be problematic 
applying this route to MLC3/ELC3 scaffolds, as the warhead might react with the hydrazide. 
 
Figure 27: In spite the resemblance of one of the synthesized compounds, the application of, the application of the Yeung et al. 
(71) synthesis is complicated by lower yields when any of the reactants are aliphatic and by the reactivity of the warhead. 
Another option for 1,2,4-triazole synthesis from nitriles is proposed by Ueda et al. (2009) 
(Figure 28). This pathway results in moderate to good yields on both aliphatic and aromatic 
substituents (52-85%). Reactants and the catalyst are widely available and affordable, and a 
wide range of FGs are tolerated (72).  
 
Figure 28: Triazole synthesis by Ueda et al. (2009) - copper-catalyzed oxidative coupling reaction of nitriles with amidines. 
4.2.1.7 Michael addition (ELC3 derivatives) 
 
Figure 29: Michael reaction is one of the most important carbon–sulfur bond forming reactions. It can be employed for the 
synthesis of ELC3 derivatives. 
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The Michael reaction traditionally takes place in organic solvent under basic conditions or in 
presence of a Lewis acid, but new catalytic methods have been developed in the recent years. 
Substituted Michael acceptors with an electron-withdrawing FG that can be transformed into a 
triazole are α,β-unsaturated esters and acrylonitriles (73). 
However, because of steric hindrance, only unsubstituted α,β-unsaturated amides can react as 
Michael acceptors by traditional methods (73). Thio-Michael addition of β-substituted 
α,β-unsaturated amides has been developed by Liu et al. (2017). The reaction takes place in 
solvent-free -methyl-morpholine-based ionic liquids at 55 °C (73). 
 
Figure 30: Thio-Michael addition of substituted α,β-unsaturated amides by Liu et al. (73). 
Metal-, catalyst-, ligand-, and solvent-free direct synthesis of 3-sulfone nitrile from sulfonyl 
hydrazides and acrylonitrile in water has been reported by Li et al. (2017). Simple 
β-monosubstituted acrylonitriles (2 mmol) were reacted with substituted sulfonyl hydrazides (1 
mmol) at 120°C for 10 h, resulting in moderate to good yields (74). Production of a sulfonyl 
hydrazide analog of MLC3 could be difficult, as hydrazine could react with the warhead in the 
same way as cysteine. 
 
Figure 31: Synthesis of 3-sulfone nitrile from sulfonyl hydrazides and acrylonitrile in water. 
The closest substituent-enzyme interaction to the MLC3 and ELC3 scaffolds that can be seen 
from the conformations of the inhibitors in crystal poses of is a hydrogen bond donor feature to 
the main backbone carbonyl of Val162. By docking of the candidate derivatives, we discovered 
that the optimal location of the H- bond donor feature (such as a hydroxy or amino FG) would 
be bound to the γ-carbon atom of the substituent relative to the scaffold sulfone.  
Chakravarthy et al. (75) report a synthesis of δ-hydroxy-α,β-unsaturated esters that proceeds 
smoothly in high yields with a variety of substrates. The mechanism is a vinylogous aldol 
reaction of unsaturated esters and aldehydes using aluminum tris(2,6-di-2-naphthylphenoxide). 
This reaction can be used for the employment of aldehydes as starting materials for the synthesis 
of Michael acceptors that can be transformed into ELC3 derivatives with a hydrogen bond 
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interaction with Val162. The yields range from 65% to 97%. The reaction is somewhat stereo-
selective (more branched aldehydes result in a higher stereoisomeric purity) (75). 
 
Figure 32: Synthesis of δ-hydroxy-α,β-unsaturated ester Michael acceptors. 
4.2.1.8 Other options 
Most of the FGs discussed can be interconverted and multiple synthetic routes are possible for 
the same starting materials. For example, amides can be dehydrated to nitriles or vice versa, 
and another synthetic path can be used that way. Carboxylic acids or acyl halides can be 
converted into acyl amidrazones and then to 1,2,4-triazoles by intramolecular condensation in 
xylenes at 180-200°C (76). Hydrazides can be acylated (with carboxylic acids or acyl halides) 
to diacyl hydrazines, which can then be converted to dichloroazines and subsequently 1,2,4-
triazoles by reaction with ammonia in alcoholic solution (6h at 180°C) (77). 
Many routes were found for (fully) 1,3,5-trisubstituted 1,2,4-triazoles, for which the option of a 
disubstituted triazole product was not reported. Often these use the same starting materials but 
are more selective or react under milder conditions. 
4.2.2 REACTIONS OF SULFONYL CARBANION 
The use of sulfonyl carbanion methods is a common and effective practice in the synthesis of 
sulfones. Although the use of sulfonyl carbanion-based reactions for derivative synthesis seems 
straightforward, it is complicated by the structure of the MLC3. The electrophilic center of the 
warhead can react with a nucleophilic base or self-condensation can occur after treatment with 
a non-nucleophilic base. 
Use of alkyl-lithium compounds is not recommended as some degree of nucleophilic 
substitution will occur between the base and the sulfonyl, additionally to that, the base might 
react with the warhead. To avoid these reactions, the addition of a non-nucleophilic base like 
Lithium diisopropylamide (LDA) or lithium bis(trimethylsilyl)amide (LiHMDS) to the sulfone-
containing scaffold should be performed at low temperatures under anhydrous conditions in 
THF or dimethoxyethane solvents. The addition should take place in the shortest time possible, 
so that the sulfone anion can react rapidly with the selected electrophile instead of undergoing 
self-condensation (Figure 33). Another option is the “Barbier” protocol, where the base is added 
to the mixture of the sulfonyl and the carbonyl compound, but this can also form enolates from 




Figure 33: If the reaction conditions are not properly adjusted, self-condensation of MLC3 is expected to be the major reaction 
after treatment with a non-nucleophilic base. 
Apart from introduction of β-oxo derivatives (Chapter 4.2.2.1), no reaction conditions could be 
found reported for sulfonyl carbanion reactions when the sulfone is attached to a π-deficient 
heterocycle. Pyrimidin-2-yl sulfone contains an electrophilic center within the heterocyclic core. 
The application of other reagents that are frequently employed for sulfonyl carbanion reactions, 
such as epoxides, aldehydes (aldol-type reactions) and Michael acceptors, is problematic for our 
purposes. The alkoxide intermediate formed in the mechanism (Intermediate 1 in Figure 34) 
would unfortunately react with the warhead in the same manner as the cysteine in the active site 
and a modified Julia olefination reaction would follow the electrophilic addition. 
 
Figure 34: Some frequently employed reagents for sulfonyl carbanion alkylation that form an alkoxide (Intermediate 1) and 




4.2.2.1 β-oxo derivatives 
Pospíšil and Sato (2011) describe a method for synthesis of β-oxoethyl sulfones with good to 
excellent yields (85-98%). They report that the reaction conditions tolerate various 
functionalities, e.g., ethers, and halogenated or unsaturated alkanes (78, 79). 
The α-carbon of the β-oxo derivatives should be at least as electrophilic as the one in the MLC3 
warhead – preserving its reactivity. As mentioned, self-condensation of sulfones proceeds 
rapidly under basic conditions. However, when lithiated (due to the use of LiHMDS), keto 
sulfones are stable under basic conditions and do not proceed with further reactions with 
nucleophiles due to the negative charge stabilization by the carbonyl group (enolate) (79). 
 
Figure 35: Synthesis of β-oxo derivatives. Modified Julia olefination is avoided due to the destabiliation of the alkoxide 




4.3 DE NOVO DESIGN (“IN SILICO SYNTHESIS”) OF DERIVATIVES 
4.3.1 LIBRARY OF COMMERCIALLY AVAILABLE COMPOUNDS 
A library of commercially available molecules was created by combining three sources of 
compound collections: ChemDiv Chemistry Building Blocks, Enamine Building Blocks, and 
MolPort. The three collections were imported into a KNIME workflow using the File Reader 
node. Two columns were read from each collection: one with the structural data and the second 
containing a string with the provider’s compound code. 
The corresponding columns were named in the same manner in all three sources and a 
Concatenate node was used to combine them into a single table. RDKit From Molecule node 
was used to replace the molecular structure column with an RDKit readable format 
(RDKit Mol). Using the RDKit Canon SMILES node, canonical SMILES were generated from 
the RDKit Mol column and appended to the table for the elimination of duplicate molecules. 
Duplicates (multiple entries of the same molecules) were eliminated with GroupBy node. The 
data tables were written with a Table Writer to a compound library file in a KNIME format 
(All_input.table) which can be read with a Table Read node. 
 
Figure 36: KNIME workflow for the preparation of the input compound library. 
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4.3.2 FILTRATION OF STARTING MATERIALS 
4.3.2.1 Nucleophilic substitution subset 
Table II: An MLC3 representative starting material scaffold for the derivatives synthesized by nucleophilic substitution 
pathways. Given are also the RDKit Substructure Filter SMARTS queries for the MLC3 and ELC3 derivative starting materials 
and the number of hits. 
Starting material # 
ELC3/ 
MLC3 
SMARTS substructure query Hits 
 
1 MLC3 C[CX4]([Cl,Br,I,SH])C(=O)[NH2] 50 
2 ELC3 [CX4]([Cl,Br,I,SH])CC(=O)[NH2] 16 
 
3a MLC3 [CX4]([Cl,Br,I,SH])C(=O)[OR0][c,CX4] 911 
4a ELC3 [CX4]([Cl,Br,I,SH])CC(=O)[OR0][c,CX4] 761 
 
3b MLC3 [CX4]([Cl,Br,I,SH])C(=O)[OR][c,CX4] 18 
4b ELC3 [CX4]([Cl,Br,I,SH])CC(=O)[OR][c,CX4] 5 
 
5 MLC3 [CX4]([Cl,Br,I,SH])C(=O)[OX-,OH] 260 
6 ELC3 [CX4]([Cl,Br,I,SH])CC(=O)[OX-,OH] 262 
 
7 MLC3 [CX4]([Cl,Br,I,SH])C(=O)[F,Cl,Br,I] 96 
8 ELC3 [CX4]([Cl,Br,I,SH])CC(=O)[F,Cl,Br,I] 14 
 
9 MLC3 [CX4]([Cl,Br,I,SH])[CX4H2][NX4H3+,NX3H2] 25 
10 ELC3 [CX4]([Cl,Br,I,SH])[CX4H2][NX4H3+,NX3H2] 37 
 
11 MLC3 [CX4]([Cl,Br,I,SH])C#N 96 





Molecules from the compound library were then filtered by the RDKit Substructure Filter for 
the necessary substructure that would lead to the synthesis of the derivatives. Table II gives 
queries for “complete synthesis” pathways involving nucleophilic substitution. The SMARTS 
patterns in the figure define the substructure (backbone) that must be included in all the filtered 
molecules. Meaning all the filtered molecules have: 
• [CX4]([Cl,Br,I,SH]) – an aliphatic carbon atom, connected to 4 atoms in total 
(sp3 hybridization). One of the connections is taken by a chlorine, bromine, iodine, or a 
thiol. Two other bonds can be either hydrogens or substituted. 
• In MLC3 derivatives the fourth bond is taken by either: 
o C(=O)[NH2] – primary amide group. 
o C(=O)[OR0][c,CX4] – ester, not embedded in a ring and either aromatic or sp3-
hybridized aliphatic (not anhydride etc.) in the alcohol-derived part. 
o C(=O)[OR][c,CX4] – lactone, either aromatic or sp3-hybridized aliphatic. 
o C(=O)[OX-,OH] – carboxylate or carboxylic acid. 
o C(=O)[F,Cl,Br,I] – an acyl halide. 
o [CX4H2][NX4H3+,NX3H2] – carbon connected to 4 atoms in total, two of them 
being hydrogens and one a primary ammonium or primary amine. 
• In the equivalent ELC3 derivative starting materials, the fourth bond is taken by (a 
substituted or unsubstituted) sp3 hybridized carbon connecting the corresponding FG.  
4.3.2.2 Michael addition subset 
A Michael addition has been suggested for the synthesis of the ELC3 derivatives. The starting 
compounds for these pathways are the electrophiles of the Michael reaction (i.e. “Michael 
acceptors”). These have a common α,β-unsaturated compound structure (enone, enal, etc.) and 
the filtration of such compounds seems straightforward. 
When libraries were filtered for the common substructure, some of the products contained an 
alkoxide FG. After tracing the products back to the starting materials, we made a discovery that 
the libraries contain enol tautomers of 1,3-dicarbonyl structures, usually stabilized by being 
salts. In the preparation of the libraries, the cation was eliminated, and a negatively charged 
alkoxide FG remained in its original form. 
While enol tautomers have a Michael acceptor-like substructure, they paradoxically act as 
Michael donors rather than acceptors (Figure 37a). Another challenge was posed by conjugated 




Figure 37: 1,3-dicarbonyl compounds behave as Michael donors, while the enol tautomer of a 1,3-dicarbonyl structure has a 
Michael acceptor-like substructure (a). Michael addition on a conjugated double bond system can proceed on either of the 
bonds (b). 
Therefore, enols and conjugated double bond-containing Michael acceptors had to be eliminated 
from the set. Lactones (cyclic esters) were treated separately from acyclic esters because of 
different subsequent processing – the alcohol-derived part could not be discarded in that case 
but had to be transformed by a ring-opening reaction to an alcohol FG. 
Figure 38 shows the complete input in the RDKit Substructure Filter node on an example of 
an ester-containing Michael acceptors (compare to entry 13a on Table III). Conditions were 




Figure 38: Substructure search for Michael acceptor reagents. FG was changed accordingly. 
Table III: Starting materials of the ELC3 derivatives using Michael addition, number of hits represents the number of molecules 



















RDKit Functional Group Filter 
Acid Chloride: 0, Sulfonyl Chloride: 0, Aliphatic Not Fluorine 
Halogen: 0, Aldehyde: 1 
40348 
Molecules with substructure from the entries 13-15 (Table III) have been acquired using the 
RDKit Substructure Filter node. Mono- or un-substituted β-position of Michael acceptors has 
been selected to avoid steric hindrance. In the case of ester starting compounds (13a on Table 
III), any carbon atom, not in a non-aromatic conjugated double bond system was tolerated, in 
order to include more reactive Michael-acceptors such as α,β-unsaturated diesters. In the case 
of lactone starting compounds, only sp3 carbons were tolerated on the β-position (cyclic and 
non-cyclic diesters would have been transformed into the same di-triazoles). 
Aldehydes (Entry 16), are starting materials for the production of δ-hydroxy-α,β-unsaturated 
esters and subsequent Michael addition. These have been found using the 
RDKit Functional Group Filter by selecting the number of desired FGs in the node 
configuration table. 
Aliphatic carbon containing at least 
one hydrogen. If substituted, only with 
sp3-hybridized or aromatic carbon. 
If substituted, then only with carbon, that 
does not form a non-aromatic conjugated 
double bond system with another carbon. 




4.3.2.3 Sulfonyl carbanion reaction reactants subset 
The scope and limitations of the agents that can be used in the sulfonyl carbanion reaction were 
extensively studied under different conditions by Pospíšil et al., using benzo[d]thiazolyl sulfone 
substrates (78, 79). Benzo[d]thiazolyl sulfone moiety can be considered as an analog of the 
pyrimidinyl sulfone warhead of the MLC3 and exhibits the same chemical reactivity. 
Table IV: All the tested reactants with a substructure represented by entries 17 and 18, were reported to result in yields above 
78% by Pospíšil et al. when using on benzo[d]thiazolyl sulfone (warhead analog) (79). 








4.3.3 STRUCTURAL TRANSFORMATIONS (“IN SILICO REACTIONS”) 
4.3.3.1 Nucleophilic substitution 
Determination of the range of FGs that can be transformed during a synthetic step is not a trivial 
task. As already mentioned, the preferred way of a sulfone introduction is nucleophilic 
substitution of a good leaving group (usually a halogen) with a thiol, followed by an oxidation 
step. The range of applicable oxidants for this purpose is broad, but the most used is mCPBA 
(61). In the case of oxidation with mCPBA, amines would be transformed into amine oxides, 
secondary alcohols to ketones, and double bonds would be turned into epoxides. 
Epoxides are very reactive and may form alkoxides that are incompatible with the warhead in 
the same mixture, so in case of any double bonds present, another oxidant must be used, and the 
range of FG transformation is changed. Many oxidants oxidize just some FGs and spare the 
others. Some molybdenum-based catalysts are selective and can oxidize thioethers into sulfones 
while preserving acetal, alcohol, aldehyde, amine, imine, oxime, nitrile, and alkene FGs (63). 
At this point we do not yet know which substituents are the best fit into the additional active site 
pockets, so we cannot predict which oxidant should be used. In addition, we do not know if, for 
example, an oxidation of a secondary alcohol to a ketone may be even desirable in some cases. 
We might even choose a specific oxidant due to its lack of selectivity in this regard. 
The avoidance of the oxidation step (use of a sulfinate salt instead of thiol) is, as already 
mentioned, not recommended as it might result in lower overall synthesis yields. We decided 
not to simply replace the leaving group with the warhead in a single step, but to follow the 
thioether oxidation procedure. In that case it is extremely likely that the oxidation will not be 
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specific for a single FG, and all thioethers in the structure will be oxidized. This might be a 
benefit, since a sulfone might provide additional interactions in the binding site by mimicking 
the mcCO of the substrate protein, or it may improve the inhibitor solubility. 
Apart from acyl halides, where the acyl-bound halogen is the more reactive one (and a hydrazide 
or an imide should be formed at first), the standard recommended synthesis plan is followed in 
the design of the workflow. The general synthesis workflow for the derivatives obtained by 
nucleophilic substitution is represented on Figure 39. 
 
Figure 39: In silico reactor workflow for ester starting compounds - part 1: Previously generated compound library table was 
imported into the workflow. For each pathway, the corresponding starting compounds were filtered based on the substructure 
requirements defined by SMARTS and transformed by using suitable reaction SMARTS and joined using the Concatenate node. 
After the import of the previously generated library of commercially available compounds 
“All_input.table” (4.3.1) by the Table reader node and substructure filtration using RDKit 
Substructure Filter node (4.3.2.1), the chemical transformation started with nucleophilic 
substitution of the halogen (or thiol) with the thioether bond using the 
RDKit One Component Reaction. Introduction of the warhead was done to the specific halogen 
previously defined in the substructure search, using reaction SMARTS in Table V. 
Afterwards, the analogous MLC3 and ELC3 precursors (containing the unoxidized warhead) 
were joined with the Concatenate node. To eliminate promiscuous binders from the generated 
compound-set, all compounds that still had any non-fluorine halogens or a thiol FG bound to an 
sp3 hybridized carbon were eliminated with RDKit Substructure Filter, along with other 
moieties: enol structures, aldehydes, carbocations, carbanions, Michael acceptors, and three-
membered heterocycles. 
  
                
      
     
      
     
           
                
                
                
        
                            
      
                             
            
                  
      
                  
      
           
                  
        
                  
        
                         
      
                  
         
          
                  
        
                  
      
                  




Table V: Reaction SMARTS for the nucleophilic substitution that replaced the halogen or the thiol FG with the unoxidized 
(thioether) precursor of the warhead. 
# 
Reaction SMARTS 



















































4.3.3.2 Triazole synthesis 
From each subset of MLC3 and ELC3 derivative precursors with the unoxidized warhead 
(products of the previous chapter), duplicates were removed using the GroupBy node (a 
bromide compound would create the same product as its chloride analog). Triazole was then 
synthesized from all the precursor moieties in the molecule. For example, if it was formed from 
an ester, then all (and only) ester residues in the starting compound were transformed into a 
triazole. The scope of other FGs that might react as well, was not considered. 
The transformation was made using reaction SMARTS given in the Table VI and the 
RDKit One Component Reaction. The product molecules were then checked for any further 
reactive moieties with RDKit Substructure Filter. If a molecule contained any, it was sent back 
to the start of the recursive loop to react again, until all such moieties were transformed. 
 
Figure 40: In silico reactor workflow for ester starting compounds - part 2: Following the nucleophilic substitution, duplicates 
were eliminated and all the precursor moieties were transformed into a triazole by a recursive loop. 
In the case of primary amine-containing derivative precursors (D on Table VI), it had to be 
explicitly stated that the nitrogen loses its charge and the hydrogens when transformed into the 
triazole, otherwise both have been preserved in the product molecules. 
In the case of ester-containing derivative precursors (C on Table VI) – both products had to be 
included in the output. Some molecules contained the derivative precursor part in the alcohol-
derived part of the ester, and those would get lost in the recursive loop of triazole synthesis if 
not specifically included (Figure 11). All the unwanted alcohol products that were not 
derivatives had to be filtered out by the MLC3 and ELC3 scaffold as the substructure criteria. 
  
                
      
     
      
     
           
                
                
                
        
                            
      
                             
            
                  
      
                  
      
           
                  
        
                  
        
                         
      
                  
         
          
                  
        
                  
      
                  




Table VI: Precursors of the triazole moiety, reaction SMARTS for the transformation and substructure search query for the 
recursive loop criteria (which molecules must be sent back to react again). 
































Figure 41: If only the triazole product of the synthesis would be specified in the products section of the reaction SMARTS, the 
resulting product of this starting material would not have been the derivative-containing part. Therefore, both products of the 
triazole synthesis had to be specified (alcohol and the triazole, separated by a dot). Side products not containing the MLC3 or 
ELC3 scaffold had to be filtered out (in this case methanol and 3-cyclohexyl-5-ethyl-1,2,4-triazole). 
4.3.3.3 Michael addition 
In all Michael acceptor-type precursors but aldehydes, Michael addition was done by turning 
the α,β-unsaturated bond into a single bond, and attaching the unoxidized warhead to the α-
carbon. Duplicates were removed (GroupBy node) and any reactive moieties have been filtered 
out in the same manner as has been done with nucleophilic substitution syntheses. 
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Products were sent through a recursive loop containing the RDKit One Component Reaction 
node transforming the precursor moieties into the triazole. In the case of lactones (13b on Table 
VII), the ring was opened concurrently with the thio-Michael addition step and the two ester 
subsets (13a and 13b on Table VII) were concatenated and processed together. 
Aldehydes are precursors of Michael acceptors for the subsequent derivative synthesis with a 
focus on a hydrogen bond donor interaction with the mcCO of Val162. The unoxidized 
(thioether) version of the final derivative was created in a single step and only the major 
stereoisomer of the product (75) was created on the newly generated hydroxy FG. 
Table VII: Derivative synthesis from Michael acceptors (13a-15): reaction SMARTS for the thio-Michael addition. Products 
are then sent through a recursive loop of triazole synthesis reaction. Aldehydes (16) represent precursors of δ-hydroxy-α,β-



























4.3.3.4 Recursive oxidation 
Nucleophilic substitution and Michael addition, both followed by the (recursive) triazole 
synthesis step, result in the unoxidized (thioether) precursors of the derivatives. Oxidation is the 
last synthetic step of these pathways. Many oxidants can be used for this purpose, with various 
effects on other FGs in the precursor molecule. selective oxidants exist, however, none of them 
is specific for a single thioether bond. 
All products of nucleophilic substitution and Michael addition were joined by the Concatenate 
node and underwent the oxidation step in a recursive loop. The oxidation was done by the 
RDKit One Component Reaction node, using the reaction SMARTS: 
• [C,c:1][SX2:2][C,c:3]>>[*:1][SX4:2](=O)(=O)[*:3] 
The molecules were then either collected or recursed back to oxidation – depending on if they 
still contained any thioether bonds (RDKit Substructure Filter “[C,c][SX2:2][C,c]”). 
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4.3.3.5 Sulfonyl carbanion reaction 
MLC3 and ELC3 derivatives obtained by the sulfonyl carbanion reaction have been created in 
a single step by the RDKit One Component Reaction node (reaction SMARTS in Table VIII).  
Table VIII: Four reactions have been performed on the two sets of starting compounds. Carbonylation reagents can be employed 
for the introduction of an ester, thioester, ketone, or amide substituent to both MLC3 and ELC3 scaffolds. 















Afterwards, all product sets have been concatenated, duplicates were removed, and reactive 
species have been eliminated as in previous pathways (Figure 42). 
 
Figure 42: Workflow for the generation of derivatives obtained by the sulfonyl carbanion reaction. 
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4.3.3.6 Generation of stereoisomers and output file 
The products of sulfonyl carbanion reaction (4.3.3.5) and recursive oxidation (4.3.3.4), the 
latter combining the products of the nucleophilic substitution (4.3.3.3) and Michael addition 
(4.3.3.1), were concatenated. All derivatives in their final (oxidized) version were hereby joined 
into a single pathway. Duplicates were removed and R- and S-stereoisomers were generated at 
the α-carbon of the derivatives using again RDKit One Component Reaction and the following 
two reaction SMARTS patterns: n1cc([CH3])cnc1[SX4:1](=[O:2])(=[O:3])[CX4:4]>> 
a) n1cc([CH3])cnc1[SX4:1](=[O:2])(=[O:3])[CX4@:4] 
b) n1cc([CH3])cnc1[SX4:1](=[O:2])(=[O:3])[CX4@@:4] 
The diastereomers were collected, and duplicates were removed (the molecules containing two 
identical substituents were in duplicates as the α-carbon was not chiral). 153675 molecules were 
retrieved, converted into SMILES representations by RDKit To Molecule. The strings (SMILES 
values) were then written out in a text file using the CSV Writer node. 
 
Figure 43: Final KNIME processing: all the products were combined; stereoisomers were generated on the α-carbon (when 
chiral), and the molecules were written out in lines as SMILES string values in a text file. 
4.4 PHARMACOPHORE OPTIMIZATION 
Three sources of information have been considered when designing the optimal pharmacophore: 
• The pharmacophore that led to the discovery of MLC3, created by Yousef et al. (35) 
• X-ray crystallographic and NMR structures of 3Cpro. 
• Docked poses of MLC3 and ELC3. 
In the preceding work by Yousef et al. (35) that resulted in the discovery of MLC3 (then called 
Compound 3), an extensive set of pharmacophores was created by combining the possible 
enzyme-inhibitor interactions proposed by PyRod (46). The 45th pharmacophore in the set 
(45.pml) provided the most accurate results when screening a set of known inhibitors and decoys 
(35). 
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45.pml was the pharmacophore that ultimately led to the discovery of MLC3 and was used as 
the main template in the pharmacophore optimization. When the pharmacophore 45.pml was 
used in its original version for the screening of MLC3 and ELC3 derivatives, it has to a large 
extent resulted in compounds fitting the pharmacophore only by various FGs (mostly amides) 
of the substituent occupying the S1 pocket, while the triazole was placed elsewhere. 
A comparison using MOE has shown that the distances between the S1 pocket hydrogen bond 
acceptor and hydrogen bond donor elements found in the 45.pml (3,08 Å) correspond better to 
the one found in the amides (2,29 Å) than to the distance between the consecutive nitrogen 
atoms in the triazole (1,34 Å). This finding corresponds to the fact that the 45.pml vas validated 
on previously known inhibitors that mostly contain a γ-lactam (a cyclic amide) in the S1 pocket. 
Because of the different chemical feature distances and a different hydrogen bonding profile, 
the rigid triazole structure can only form two hydrogen bond interactions in the S1 pocket, while 
the amide FG forms three. Triazole is a novel feature of MLC3 that does not seem to allow the 
same binding mode as the inhibitors containing an amide moiety in the P1 position. 
The pharmacophore-based virtual screening aimed to find a set of properly fitting “fragment 
grown” derivatives with the triazole placed in the S1 pocket. Therefore, the pharmacophore 
described by Yousef (35) mentioned in the instroduction on page 8 had to be adapted to the 
binding mode of the MLC3 to place the triazole in its optimal relation to the other features of 
the pharmacophore for the proper evaluation of the derivatives. 
Docking of unsubstituted MLC3 and ELC3 was used to observe preferred positions of the 
triazole with respect to the active site and resulted in the suggestion of two possible binding 
hypotheses of the triazole in the S1 pocket. The binding hypotheses provide a possible 
explanation of why the distance between the hydrogen bond donor and acceptor feature seem to 
be suboptimal when compared to the 45.pml pharmacophore. To investigate the binding 
possibilities of derivatives, two pharmacophores were generated by combining the the 
pharmacophore described by Yousef (35) template with the S1 pocket interactions adapted to 
either of the two poses suggested by docking.  
The His161 residue has a more stable position than Thr142 when considering atom B-factors 
from the unbound crystal structure (80). The B-factor is a measure of the disorder in the atomic 
position caused either by the thermal vibration or subtle structural differences in the unit cells 
of the crystal. A B-factor of less than 30 Å2 indicates a stable atomic position, while a B-factor 
higher than 60 Å2 indicates that the atom is disordered (81). In the ligand-free PDB structure 
file 3ZV8 (5), the Oγ atom and the mcCO atom of Thr142 have a B-factor of 67.15 Å2 and 68.66 
Å2 respectively, compared to 29.62 Å2 for the NE2 atom of His161. 
The S1 pocket 3Cpro-MLC3 interactions of the binding hypothesis 1 include the mcCO and the 
Oγ of Thr142. For the generation of the first pharmacophore, the S1 pocket features from the 
45.pml were placed in the position of corresponding locations of the triazole nitrogen atoms in 
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the docked pose of MLC3. Because of the high B-factors (5), which suggest a high positional 
instability of both Thr142 atoms involved in hydrogen bonding, the connected features were 
represented by spheres (Figure 44). 
 
Figure 44: The docked poses of MLC3 and ELC3 (binding hypothesis 1) next to the 45.pml pharmacophore (left image) and 
the optimized pharmacophore (right image) S1 pocket features. 
The binding hypothesis 2 involves a hydrogen bond donor feature to the Oγ of Thr142 and a 
hydrogen bond acceptor feature to His161. Due to the consistency of the location of the carbonyl 
group of the lactam-containing inhibitors and the relative stability of the His161 as indicated by 
the B-factor (5), the hydrogen bond acceptor feature from His161 has been kept in a vector form 
in the pharmacophore (Figure 45). 
 
Figure 45: The docked poses of MLC3 and ELC3 (binding hypothesis 2) along with the 45.pml pharmacophore (left image) and 
the optimized pharmacophore (right image) S1 pocket features. The hydrogen bond donor feature on the right image (green 




The hydrogen bond donor feature in the binding hypothesis 2 is not invariably connected to an 
interaction with a specific enzyme atom and is rather a reflection of the (fixed) distance between 
the consecutive nitrogen atoms of the triazole and the docking pose of the triazole. Due to the 
stability of His161 and the flexibility of the Thr142, the resulting pharmacophore might also 
cover the binding hypothesis 3, where the interactions are made between the His161 and Thr142 
mcCO. In binding hypothesis 3, the active site needs to adapt to the scaffold (from the water-
stabilized conformations used in the docking). When considering the B-factors (5), it is more 
likely that the His161 keeps its place in this situation, and the position of Thr142 is adapted to 
the triazole in the induced fit. 
For the pharmacophore optimization, it does not matter that the MLC3 can bind in all its 
tautomer variations. The importance resides with the feature type, feature location, and feature 
direction. All our derivatives are standardized to the same (predominant) tautomer, and the 
pharmacophore is adjusted to fit that tautomeric structure concerning whether the feature should 
be a hydrogen bond donor or an acceptor. 
4.5 IN SILICO ASSESSMENT OF DERIVATIVES  
4.5.1 EV68-3CPRO BINDING 
7565 molecules have been retrieved from the pharmacophore-based virtual screening using the 
pharmacophore corresponding to the binding hypothesis 1 and 3139 molecules have been 
retrieved using the pharmacophore corresponding to the binding hypothesis 2. A maximum of 
ten binding poses have been generated for each molecule using GOLD. 
After docking, the conformations have been energy minimized using SZYBKI (40) and the 
energy minimized poses have been rescored to the pharmacophore using LigandScout (37). 
Conformations with a score of 30 or more have been considered for further selection – these are 
the derivative conformations that preserved the original MLC3 or ELC3 scaffold interactions. 
Further selection was done by visual inspection using a multiple criteria decision: 
• Conformations with considerable solvent-exposed lipophilic areas were excluded. 
• Only conformations allowing the mechanism of the inhibition were included. 
• Favorable interactions were examined using LigandScout along with the pharmacophore 
with combined all PyRod-proposed interactions, and the visual representation of the 
molecule in the active site using MOE. 
• The molecule can be obtained from the starting material by the proposed synthetic route. 
• Drug-like molecules were given preference (lipophilicity, molecular mass and the 




Table IX: Promising derivatives for 3Cpro inhibition have been named according to the scaffold (M for MLC3; E for ELC3), 
the letters T or H indicate the binding hypothesis (T for binding mode 1 and H for binding mode 2). The first number indicates 
the direction of the substituent in the active site (2 -reaching towards S2 pocket; 3 – reaching towards S3/S4 pockets) 
Code Structure Starting material 








































































Out of nineteen derivatives, only three are MLC3 derivatives, and sixteen are ELC3. Both α-
carbon enantiomers are present among the selection – five are S and fourteen R. Twelve of the 
derivatives are produced by an aldol reaction of unsaturated esters with an aldehyde, producing 
a δ-hydroxy-α,β-unsaturated ester (a Michael acceptor). The ester can then react with a 5-
methyl-2-thiopirimidine and oxidized into the ELC3 derivative. These derivatives can be easily 
recognized by the hydroxy group on the second carbon atom of the substituent and were 
originally developed to form a hydrogen bond between the hydroxy group and the mcCO of 
Val162. That specific interaction is formed only with EH-202, while ET-301 accepts a 
hydrogen bond from the main chain nitrogen of the proximate Gly164 and donates a hydrogen 
bond toward the mcCO of the same residue, and ET-305 donates a hydrogen bond to His40. 
The enantiomer that corresponds to the product with the highest yield (75) has been generated 
and screened in every derivative of this type. 
Six derivatives are synthesized using the sulfonyl anion pathway. The reactions, scope of the 
reagents, and the reaction conditions are described by Pospíšil and Sato (2011) (78, 79). These 
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reactions are reported to result in good to excellent yields (85-98%) and are the most reliable 
synthetic pathways for the derivatives. The derivatives can be recognized by the carbonyl group 
on the first atom of the substituent. 
One derivative (ET-203) is synthesized using the Michael addition and is especially interesting 
because it rigidifies the ELC3 scaffold in a six-membered piperidine ring. Such derivatives 
could have only been produced by the Michael acceptor route. 
The energy minimized docking poses of the derivatives in the active site are attached in the 
supplementary data (7.1 Docked Poses). 
4.5.2 SARS-COV-2-3CLPRO BINDING 
A docking experiment of the proposed derivatives has shown that the triazole may be recognized 
as a substrate by the S1 pocket of SARS-CoV-2-3CLpro, and that five of the previously listed 
derivatives (MT-202, ET-202, ET-203, EH-203, and EH-302) show a potential of non-covalent 
interaction with the SARS-CoV-2-3CLpro that corresponds to the presumed EV68-3Cpro binding 
pose (Figure 46). 
 
Figure 46: Top-view of the docking poses of MT-202, ET-202, ET-203, EH-203, and EH-302 inside the active site of the SARS-
CoV-2-3CLpro represented by surface area. The triazole of the derivatives is placed in the S1 pocket and interacts with His163 
(the histidine corresponding to the His161 of EV68-3Cpro). The active site nucleophile Cys145 is represented by the yellow-
colored surface below the sulfone FG of the derivatives. 
On the docking poses, the warhead gets shifted towards the S1’ or the S2 pockets and seems to 
be too large to allow the active pose and a covalent reaction with Cys145 (Figure 46). The S1′ 
site of the 3Cpro is more open than the S1′ site of the 3CLpro. A similar conclusion has been 
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drawn by Lee et al. (82), who report that an addition of a cyclopropyl group in the P1’ region of 
peptidomimetic inhibitors enhanced the inhibition against CVB3-3Cpro fourfold, but caused 
steric clashes with the atoms of the SARS-CoV-3CLpro, making the compound a much weaker 
3CLpro inhibitor. 
The 1-methyl-1H-tetrazol-5-yl sulfone analog of the warhead is the smallest reported functional 
analog of the pyrimidine warhead and can easily be prepared from inexpensive starting materials 
(83). The elimination of the 5-methyl substituent (that is not involved in the mechanism of 
action) might already alone improve the 3CLpro affinity of the derivatives. 
4.6 STRUCTURE-ACTIVITY RELATIONSHIP 
4.6.1 MLC3 STRUCTURAL ANALOGS 
Thirteen commercially available structural analogs have been found in Enamine. The 
compounds picked for SAR establishment were selected according to their modifications on one 
of four structural regions of MLC3. M-A01 and E-W01 show variations in the linker-part; M-
A01 has an alpha-substituted carbon-atom, which could show, how the alpha-substitution 
influences the binding affinity of MLC-3-like scaffolds and if steric hindrance poses a big risk 
to the activity. E-W01 was the closest molecule to an ELC3 derivative we found. The 
unoxidized version is likely inactive as an irreversible inhibitor, but a single oxidation step might 
provide valuable information on the binding affinity change from MLC3 to ELC3 modification. 
M-E01 and M-E02 give valuable information on the steric effects of the ethyl-tail region. The 
ethyl-tail is not predicted to contribute to the binding of the MLC3, so a methyl-tail analog (M-
E01) might have a higher affinity by a lesser chance of steric hindrance of the binding. An 
isopropyl-tail analog (M-E02) is in that way a negative control 
M-T01, M-T02, and M-T03 give information on the triazole binding mode. M-T01 does not 
have a hydrogen bond donor feature and therefore does not allow the binding hypothesis 1 and 
represents a “stabilized” MLC3 4H-1,2,4-triazole tautomer analog. M-T02 and M-T03 are very 
similar to the P1 parts of Michael addition inhibitors and can indicate whether the Warhead 
modification or the triazole is the reason for the unusually high affinity of the MLC3 
considering its size. 
The warhead modification M-W01 should be inactive when considering the reported data on the 
chemical reactivity of the warhead moiety (60). The analogs M-W02, M-W03, M-W04, and 
M-W05 join the negative effect of the pyridine instead of a pyrimidine warhead and a positive 
effect of an electron-withdrawing group on the 5-position. M-W06 gives information on the 




Table X Commercially available structural analogs of MLC3 with arrows indicating the change 










































5 SUMMARY AND OUTLOOK 
Viruses from the picornavirus-like supercluster are widespread, cause frequent outbreaks and 
serious socioeconomic harm throughout the world. Symptoms of infection are non-specific, can 
affect any of the vital organs, and in rare cases lead to death of the patient. As of now, there are 
no curative treatments available. Management of the diseases caused by these viruses has been 
directed towards the use of strain-specific preventative vaccination, promotion of hygiene, and 
symptomatic treatment of infections. 
3Cpro and 3CLpro have a high conservation within the families and a central role in the viral 
replication and proliferation by cleavage of the polyprotein into functional proteins. Several 
inhibitors with broad-spectrum activity against picornaviral 3Cpro, caliciviral 3CLpro and 
coronaviral 3CLpro are known. These agents are targeting broadly conserved viral enzymatic 
active sites whose structure directs the virus replication efficiency. Broad-spectrum 3C/3CLpro 
inhibitors were one of the first starting resources for drug design tackling the COVID-19. For 
example, GC376 is regarded as one of the most potent SARS-CoV-2-3CLpro inhibitors in vitro 
(IC50 = 0.030 ± 0.008 µM) even though its discovery precedes the COVID-19 emergence (84). 
As CoV infections are common in animals that live near human habitats, there is a constant risk 
of cross-species transmission and a reemergence of a new viral pandemic. Research, discovery, 
and development of new effective antivirals are therefore of vital importance. A novel-type 
irreversible EV68-3Cpro inhibitor has been discovered in 2019 by Yousef et al. (35) at the 
Institute of Pharmacy of Freie Universität Berlin by in silico evaluation and assays of 
commercially available compounds containing Meisenheimer complex-forming substructures. 
The inhibitor (Compound 3, renamed to MLC3 in this thesis), exhibits an IC50 value of 
16.6 ± 2.1 μM. Within the process of drug design and development, it can be regarded as a hit 
that needs optimization to a more potent compound before entering preclinical studies.  
Optimization was mainly done using the fragment growing approach that proposed derivatives 
forming additional interactions with the active site while retaining the original ones. 
Retrosynthetic analysis was employed to rationalize the selection of derivatives for which the 
precursors can be purchased and can potentially be synthesized using the reaction conditions 
reported in the literature. The set of test compounds was created using KNIME “in silico reactor” 
workflow, by searching for commercially available starting materials and transforming them 
into end-product derivatives for subsequent in silico enzyme binding evaluation. 
The EV68-3Cpro crystal structures by Tan et al. (5) were helpful as a practical display of the 
intermolecular bonds that can be formed with the enzyme and were the main argument behind 
the decision of the fragment growing from the α-carbon. Furthermore, the crystal structures 
complemented the retrosynthetic analysis by the design of specific synthetic routes that would 
introduce functional groups that had a potential for interaction with the enzyme. The comparison 
of the docked poses of MLC3 and ELC3 with the crystal structures has shown that the substrate 
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backbone interactions could be targeted by the introduction of a hydroxy FG on the second 
carbon atom of the substituent. 
The determination of the scope of all the FGs that would change during a reaction is not a simple 
task and only the original FGs intended to change were reacted in each pathway. An interesting 
suggestion is to consider the scope of oxidations of different oxidants on common FGs and 
accordingly derive several different pathways resulting in different products. That would expand 
the chemical space only by a different choice of an oxidant with no additional synthetic steps. 
Ester 1,2,4-triazole precursors had the whole alcoholic part removed (by a transformation to a 
hydrazide). It sometimes happened that the ester moiety was chemically rich in the alcohol-
derived part and the carboxylic acid-derived part was chemically simple or even identical in 
multiple cases. It would be reasonable to filter such compounds out as they lead to reactions 
with a low atom economy and the cost usually reflects the complexity of the removed side 
product. The chances of side reactions are also higher, and there is a buildup of side products 
that need to be eliminated if those reactions are used. 
Retrosynthesis and the pharmacodynamics of covalent inhibition are connected by common 
chemistry. In the mechanism of inhibition, the more nucleophilic thiol FG binds to the 
pyrimidine and eventually replaces the sulfone FG, as the latter is a better leaving group from 
the thiol. These relations were exploited in the synthetic step order – the leaving group halogen 
should be replaced by a more stable thioether bond in the first steps to lessen the side reaction 
risk, while the oxidation of the thioether to the reactive warhead should be made in the last step. 
Sulfonyl-carbanion reactions were at first considered for the enormous scope of derivatives that 
could be produced using common reactive electrophilic species such as haloalkanes, epoxides, 
aldehydes, etc. In the end, most were found to be incompatible due to an alkoxide intermediate 
that would proceed with a modified Julia olefination side reaction. Determination of reaction 
conditions was another challenging area affecting all those reactants. Due to the self-
condensation of MLC3 and ELC3 (reaction of the sulfonyl-carbanion with the electrophilic 
center of the warhead), the usual reaction procedures cannot be used. 
No reports of π-deficient aryl-sulfones reactions with the mentioned common reagents were 
found, therefore the mentioned “standard” (61) sulfonyl-carbanion electrophiles could not be 
reliably used as a starting material. Instead, a report of β-oxo derivative synthesis (79) was found 
- using more reactive species containing electronegative leaving groups that destabilize the 
alkoxide intermediate (e.g. acyl halides). The electronegative leaving groups rapidly capture the 
negative charge and detach from the intermediate, preventing the modified Julia olefination. 
The original pharmacophore the pharmacophore used by Yousef et al. (35) that led to the 
discovery of MLC3, was found to be unsuitable for the MLC3 optimization purposes. The 
distance between the two consecutive nitrogen atoms of the triazole does not match the distances 
found in the amide-containing moieties usually occupying the S1 pocket, neither the distance 
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suggested by the pharmacophore created by Yousef et al. (35) as the pharmacophore was 
validated upon amide-containing inhibitors. An adjustment of the S1 pocket features of the 
pharmacophore was used to put the triazole moiety in its optimal position concerning other 
chemical features. Two binding hypotheses were proposed. 
Standard rigid docking and energy minimization do not perform well when the hydrogen bond 
binding mode of the ligand is expected to differ from the water binding patterns. The 
Thr-(H)N-(H)His bridge cannot be recognized by a rigid binding site optimized in MD 
simulations where a water molecule forms the same interaction, as in this case, a single atom 
stabilizes the bridge and the “rigidified” structure may not be able to accommodate the two 
atoms of the triazole. 
Our original research plan was to investigate the SAR structural analogs for their activity first 
on the EV68-3Cpro and on the SARS-CoV-2-3CLpro. Unfortunately, the COVID-19 pandemic 
has prevented us from performing lab work and acquiring the SAR information in due time. The 
SAR knowledge should be conjoined with the derivative optimization and the workflows 
accordingly updated – some of the synthetic routes like sulfonyl anion reactions are universal 
(the sulfone group being necessary for the covalent reactivity) and may be applied in the 
syntheses of derivatives bearing another SAR scaffold. 
Not only was the retrosynthetic approach rational by providing hits that are accessible through 
chemical modification of purchasable compounds that can be produced with the fewest synthetic 
steps through predefined standard chemical reactions; retrosynthesis was furthermore useful for 
gaining information on likely binding interactions. The retrosynthetic derivatization represents 
virtualization of the SAR studies and the “trial and error” procedures used in drug development 
for decades before the advances of the digital age, but offers two big advantages: time and 
expenses have been greatly spared. It enables in silico research of the active site concurrently 
with the in vitro SAR studies of the backbone. Minor modifications (changes in the ethyl-tail 
region, MLC3 to ELC3 etc.) can be considered using the same starting materials and applied 
in preexisting virtual reactor workflows with no actual synthesis needed between them. 
Nineteen derivatives and thirteen structural analogs are proposed for the synthesis/purchase and 
subsequent in vitro testing. The ethyl-tail and the 5-methyl group of the warhead do not 
contribute to the mechanism of inhibition or the binding and can be substituted or eliminated. 
The 5-methyl group of the warhead might even render the derivatives inactive on the SARS-
CoV-2-3CLpro, as the warhead appears to be too bulky to be incorporated in its S1’ pocket. 
Besides proposing new antiviral compounds, this thesis describes the continuous development 
of a methodological tool-set for retrosynthesis, the critical adjustment of all used software 
components using rationalized chemistry for pharmacophore optimization, the concurrent in 
silico consideration of various binding modes, and the accompanying binding hypotheses which 
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7 SUPPLEMENTARY DATA 
7.1 DOCKED POSES OF SELECTED DERIVATIVES 
 
Figure 47: The docked pose of MT-201 in the EV68-3Cpro 
 




































































Figure 65: The docked pose of EH-302 in the EV68-3Cpro 
